

## Harmonised Technical Guidance for eCTD Submissions in the EU

### Version 5.0

Prepared by the Human Harmonisation Group as new version 5.0	Until November 2021
Adoption (version 5.0) by the eSubmission Expert Group	17 December 2021
Date for coming into effect (version 5.0)	1 February 2022

## Table of Contents

### Contents

Table of Contents .....	2
List of Tables.....	5
<b>1. INTRODUCTION.....</b>	<b>6</b>
<b>1.1 GLOSSARY .....</b>	<b>7</b>
<b>2. GENERAL CONSIDERATIONS.....</b>	<b>8</b>
<b>2.1 SCOPE .....</b>	<b>8</b>
2.1.1 Types of Product.....	8
2.1.2 Types of Submission.....	8
2.1.3 Types of Submission Units .....	8
2.1.4 Types of Procedures .....	8
2.1.5 Exceptions .....	8
<b>2.2 STRUCTURE OF SUBMISSIONS.....</b>	<b>8</b>
<b>2.3 TRANSITIONAL ARRANGEMENTS.....</b>	<b>9</b>
<b>2.4 CHANGE TO ECTD FORMAT .....</b>	<b>9</b>
<b>2.5 GENERAL SUBMISSION CONSIDERATIONS .....</b>	<b>10</b>
2.5.1 Document Granularity.....	10
2.5.2 File Naming .....	10
2.5.3 Placement of Documents.....	10
<b>2.6 CORRESPONDENCE .....</b>	<b>10</b>
<b>2.7 PAPER REQUIREMENTS .....</b>	<b>11</b>
<b>2.8 HARDWARE.....</b>	<b>11</b>
<b>2.9 GENERAL TECHNICAL ECTD INFORMATION .....</b>	<b>11</b>
2.9.1 Identifier for Applications.....	11
2.9.2 File Formats.....	11
2.9.3 Portable Document Format (PDF).....	11
2.9.4 Sequence Numbers.....	12
2.9.5 Related Sequence.....	12
2.9.6 Leaf Lifecycle Operation Attributes .....	13
2.9.7 Bookmarks and Hypertext Links.....	15
2.9.8 Node Extensions .....	15
2.9.9 Extensible Mark-up Language (XML).....	15
2.9.10 Other File Formats .....	15
2.9.11 Technical Validation of eCTD Submissions .....	16
<b>2.10 OTHER TECHNICAL INFORMATION .....</b>	<b>17</b>
2.10.1 Protection against Malware.....	17
2.10.2 Security Settings .....	17
2.10.3 Signatures.....	17
<b>2.11 TECHNICAL BASELINE APPLICATIONS .....</b>	<b>18</b>
2.11.1 Baselines Starting as Sequence 0000 .....	18
2.11.2 Baselines Starting Later in Lifecycle .....	18
2.11.3 Re-Baselining a Broken eCTD Lifecycle .....	19
<b>2.12 PROCEDURE FOR SENDING ELECTRONIC INFORMATION.....</b>	<b>21</b>
2.12.1 Portals/Gateways.....	21

2.12.2	CD / DVD.....	22
2.12.4	EudraLink / e-Mail (where applicable).....	22
<b>3.</b>	<b>MODULE SPECIFIC INFORMATION.....</b>	<b>23</b>
<b>3.1</b>	<b>GENERAL INFORMATION.....</b>	<b>23</b>
<b>3.2</b>	<b>MODULE 1 ECTD ENVELOPE, ADMINISTRATIVE INFORMATION AND PRESCRIBING INFORMATION FOLDER.....</b>	<b>23</b>
3.2.1	General Considerations.....	23
3.2.2	Creation and Management of Envelope Information.....	23
3.2.3	Module 1.0 Containing Cover Letter and Tracking Table.....	24
3.2.4	Application Forms.....	25
3.2.5	Product information.....	25
3.2.6	Use of Response Documents Section.....	25
3.2.7	Use of the Additional Data Section.....	26
<b>3.3</b>	<b>MODULE 2 OVERVIEWS AND SUMMARIES FOLDER.....</b>	<b>26</b>
3.3.1	General Considerations.....	26
3.3.2	Structure of Module 2 Documents.....	26
<b>3.4</b>	<b>MODULE 3 QUALITY FOLDER.....</b>	<b>27</b>
3.4.1	Module 32S drug substance.....	27
3.4.2	Module 32p drug product.....	28
<b>3.5</b>	<b>MODULE 4 NONCLINICAL STUDY REPORTS FOLDER.....</b>	<b>29</b>
3.5.1	Guidance on the Handling of Granular Study Reports.....	29
<b>3.6</b>	<b>MODULE 5 CLINICAL STUDY REPORTS FOLDER.....</b>	<b>30</b>
3.6.1	Management and Handling of Multiple Indications.....	30
3.6.2	Management and Handling of Granular Clinical Study Reports.....	30
3.6.3	Provision of CRFs and Data when Requested.....	30
3.6.4	Provision of Synopses of Individual Studies.....	30
3.6.5	Company Core Data Sheet.....	30
<b>4.</b>	<b>ADVICE ON SPECIFIC APPLICATION TYPES.....</b>	<b>31</b>
<b>4.1</b>	<b>NEW MA APPLICATIONS.....</b>	<b>31</b>
<b>4.2</b>	<b>VARIATION APPLICATIONS.....</b>	<b>32</b>
<b>4.3</b>	<b>EXTENSION SUBMISSIONS.....</b>	<b>34</b>
<b>4.4</b>	<b>RENEWAL SUBMISSIONS.....</b>	<b>34</b>
<b>4.5</b>	<b>PSURs.....</b>	<b>35</b>
<b>4.6</b>	<b>REFERRALS.....</b>	<b>37</b>
4.6.1	CMDh referrals related to MRP/DCP/RUP.....	37
4.6.2	EMA-led referral procedures.....	37
<b>4.7</b>	<b>ACTIVE SUBSTANCE MASTER FILES.....</b>	<b>37</b>
<b>4.8</b>	<b>VACCINE ANTIGEN MASTER FILES.....</b>	<b>38</b>
<b>4.9</b>	<b>PLASMA MASTER FILES (PMFs) AND MEDICINAL PRODUCTS CONTAINING PMFs.....</b>	<b>38</b>
4.9.1	Plasma Master Files.....	38
4.9.2	Medicinal products containing PMFs.....	38
<b>4.10</b>	<b>APPLICANT INITIATED WITHDRAWALS OF THE MA OR CERTAIN STRENGTHS OR DOSAGE FORMS</b>	<b>38</b>
<b>4.11</b>	<b>APPLICANT WITHDRAWAL OR AGENCY REJECTIONS OF POST-AUTHORISATION REGULATORY</b>	<b>39</b>
<b>4.12</b>	<b>PUBLICATION OF CLINICAL DATA FOR MEDICINAL PRODUCTS.....</b>	<b>39</b>
<b>4.13</b>	<b>DUPLICATE APPLICATIONS.....</b>	<b>39</b>
<b>4.14</b>	<b>INFORMED CONSENT APPLICATIONS.....</b>	<b>40</b>
<b>ANNEX 1:</b>	<b>ECTD REFERENCE DOCUMENTS.....</b>	<b>41</b>

<b>ANNEX 2: TRACKING TABLE EXAMPLE.....</b>	<b>42</b>
<b>A2-1 INTRODUCTION .....</b>	<b>42</b>
<b>A2-2 TRACKING TABLE EXAMPLE FOR CP AND NP.....</b>	<b>42</b>
<b>ANNEX 3: GUIDANCE AND BEST PRACTICE ON THE STRUCTURE OF MODULE 3.....</b>	<b>44</b>
<b>A3-1 INTRODUCTION .....</b>	<b>44</b>
A3-1.1 Terminology in the eCTD modul 3 XML .....	44
<b>A3-2 GENERAL PRINCIPLES .....</b>	<b>44</b>
A3-2.1 Document Granularity.....	44
A3-2.2 Identifying to an Agency what the Application covers.....	44
<b>A3-3 MODULE 3 XML ATTRIBUTES IN THE ECTD.....</b>	<b>45</b>
A3-3.1 Choosing Module 3 XML Attributes .....	45
A3-3.2 Drug Substance (32s) Attributes .....	45
A3-3.3 Drug Product (32p) – Product/Dosage Form/Manufacturer .....	46
A3-3.4 Excipients.....	47
<b>ANNEX 4 MANAGEMENT OF PARALLEL VARIATIONS IN THE ECTD.....</b>	<b>48</b>
<b>A4-1 BACKGROUND.....</b>	<b>48</b>
<b>A4-2 BUSINESS CHALLENGE .....</b>	<b>48</b>
<b>A4-3 BEST PRACTICE .....</b>	<b>48</b>
<b>A4-4 DESCRIPTION OF FIGURES .....</b>	<b>49</b>
A4-4.1 Use of one Lifecycle (Option 1).....	49
A4-4.2 Creation of separate Approved and Proposed Document Lifecycles (Option 2).....	50

## List of Tables

Table 1 : Example of a PSUSA .....	12
Table 2 : Example of a Referral for CAPs .....	13
Table 3 : Example of a Referral for NAPs .....	13
Table 4 : Repeatable Elements and Attributes that Define Different Sections.....	14
Table 5 : Example for starting an eCTD with a baseline sequence .....	18
Table 6 : Example for starting an eCTD with regulatory activity sequence .....	18
Table 7 : Examples of Filenames and Leaf Titles for Response Documents.....	26
Table 8 : MAA – Centralised Procedure .....	31
Table 9 : Centralised Procedure - Outside eCTD via EudraLink .....	32
Table 10 : New MAA – Decentralised Procedure .....	32
Table 11 : Type II Variations – Centralised Procedure.....	33
Table 12 : Type IA & IB Variations – Centralised Procedure .....	33
Table 13 : Type IB Variations with linguistic review - Centralised Procedure .....	33
Table 14 : Renewals .....	35
Table 15 : Centralised Procedure – Outside eCTD via EudraLink .....	35

# 1. Introduction

This guidance document is intended to assist pharmaceutical companies with the submission of regulatory information in electronic Common Technical Document format (eCTD) to the National Competent Authorities (NCAs) and the European Medicines Agency (EMA). Also, the guidance aims to be used by the NCAs to harmonise the requirements on eCTD submissions in EU/EEA.

The eCTD format is mandatory to use for all regulatory submissions within all procedure types within EU/EEA, i.e. centralised, decentralised, mutual recognition and national procedures. The eCTD format is also mandatory for any related ASMF, both the Applicant's and the Restricted part,

This document is an important guidance to harmonise the use of eCTD within EU/EEA and is regularly updated in the light of changes in national and/or EU legislation and agreements in the network. If needed, there are also Q&A documents published in between versions of this guidance as a response on change requests or new requirements to be addressed. In addition, there are some procedure specific guidance documents published. These documents and other relevant information about eCTD and electronic submissions can be found at the [EMA eSubmission website](#).

## 1.1 Glossary

A brief glossary of terms (for the purpose of this document only) is indicated below:

Term	Definition
Applicant	The company requesting a Marketing Authorisation for a medicinal product.
Applicant's Information	Regulatory information submitted by an <b>applicant</b> to obtain or maintain a marketing authorisation that falls within the scope of this guidance document.
Active Substance Master File holder	The company who is the legal owner of an Active Substance Master File as documentation of the manufacturing of an active substance.
eCTD application, also known as a dossier	A collection of electronic documents compiled by a pharmaceutical company or its agent in compliance with European legislation and guidelines in order to seek a marketing authorisation or any amendments thereof. An <b>eCTD application</b> may comprise a number of <b>regulatory activities</b> . In the EU an eCTD application may comprise several dosage forms and/or strengths, all under one invented product name. This is understood to be equivalent to a Global Marketing Authorisation according to Art. 6 para 2 Dir. 2001/83/EC as amended.
Procedure	A registration procedure for the authorisation of medicinal products within the EU. There are four different types of procedures within the EU – Centralised, Decentralised, Mutual Recognition and National.
Regulatory Activity	A <b>single sequence</b> or a <b>collection of sequences</b> covering the start to the end of a specific business process, e.g. an MA application or Type II variation. To allow a more precise handling, the regulatory activity will be classified using a controlled vocabulary (submission type or regulatory activity type) and a free text field for a short narrative description.
Sequence	A single set of information and / or electronic documents submitted at one particular time by the applicant either as a part of or as the complete application. Any collection of content assembled in accordance with the eCTD specification (ICH and EU) is described using metadata as defined by the EU envelope. Sequences may be related to one another within one regulatory activity. The related sequence number should always be stated. In case of activities with only one sequence the same sequence number is used.
Submission Type	The submission type describes the <b>regulatory activity</b> to which the content is submitted.
Submission Unit Type	The submission unit type element of the envelope metadata set describes the content at a lower level (a "sub-activity") which is submitted in relation to a defined regulatory activity such as the initial submission, the applicant response to validation issues or list of questions or any other additional information.

## 2. General Considerations

### 2.1 Scope

#### 2.1.1 Types of Product

This guidance covers the submission of electronic regulatory information for all *human* medicinal products falling within the competence of NCAs in the EU/EEA as well as the EMA. This includes, but is not limited to, both prescription and over the counter medicinal product submissions, as innovative, generic and biosimilar product submissions. The product types include for example small molecules, biotech products, herbals, vaccines, homeopathic products or blood products.

#### 2.1.2 Types of Submission

This guidance applies to all submissions related to the authorisation and maintenance of medicinal products, including new marketing authorisations, extensions, variations, renewals, PSURs (including PSUR Single Assessment PSUSA), Active Substance Master Files (ASMF), Plasma Master Files (PMF) and withdrawals, submission of redacted clinical trial reports as well as any kind of paediatric submissions and referral related or post authorisation measures related submissions (e.g. PASS, PSUFU, Referrals, Signals). For variations, PSUSAs, ASMF and PMF there are also specific guidance documents (see references in [Annex 1](#)).

#### 2.1.3 Types of Submission Units

The submission units allow sequences that make up a Regulatory Activity to be grouped together. It describes the submission steps within a Regulatory Activity, such as initial, validation-response, response and closing in case of a new MAA.

The submission unit 'additional-info' should be used for additional information (which could include, for example, missing files), and should only be used when 'validation-response' or 'response' is not suitable. Submission unit 'consolidation' should be used for applicant's withdrawals and authorities' rejections of a specific regulatory activity to bring the dossier back to the previous state. The submission type 'corrigendum' should only be used in exceptional circumstances in the CP to correct information, typically for product information, after the Regulatory Activity has concluded.

#### 2.1.4 Types of Procedures

This guidance covers applications made in any of the applicable procedures, i.e. National Procedures (NP), Mutual Recognition Procedures (MRP), Decentralised Procedures (DCP) and Centralised Procedures (CP) within EU/EEA. For submissions within MRP and DCP, please also refer to the specific CMDh guidance '[CMDh Best Practice Guide on the use of eCTD in the MRP/DCP](#)'.

#### 2.1.5 Exceptions

This guidance does not apply to the electronic submission of pre-marketing authorisation (MA) information such as scientific advice, clinical trial applications, orphan drug designations, PIP submissions and related submission correspondence as well as dossier content explicitly excluded from the commonly maintained electronic dossier. These exceptions may be subject to change in the future. (Please, refer to the EMA eSubmission website and to CMDh website on eSubmission for any future updates.)

## 2.2 Structure of Submissions

This document provides guidance on how to organise application information for electronic submission using the eCTD specifications. Guidance on the detailed information to be included is described in the [Common Technical Document \(CTD\)](#), and relevant ICH and EU Q&A documents.

The structure and organisation of an eCTD submission is defined by the following standards:

- ICH M2 eCTD Specification
- EU Module 1 Specification
- Relevant ICH and EU Q&A and guidelines

[Annex 1](#) contains links to the currently approved version of these documents and other useful references.



Typically, an eCTD application will cover all dosage forms and strengths of a product. In the Centralised Procedure, this will be equivalent to all dosage forms and strengths covered by an EMA application number (e.g. EMEA/H/C/000123). In MRP/DCP, a single eCTD should preferably be used for the full procedure covered by a procedure number (e.g. SE/H/0014/001-003). However, if an applicant decides not to apply for all strengths and dosage forms in every member state in the procedure, the possibility of having one eCTD application per strength/dosage form could be considered but is normally not recommended. Applicants should carefully consider what an eCTD application should cover before submitting the first sequence, as the choice could have implications for the workload for the entire lifespan of the product. For example, if the applicant decides to have one eCTD per strength or dosage form, it is expected that each of these eCTD applications will be maintained individually, such that submission of a single sequence that covers more than one strength or dosage form will not be possible. In rare cases where a change is needed, please contact the NCA/RMS/EMA concerned at an early planning stage.

Note that choosing separate eCTD lifecycles for each strength or form of a national (MRP/DCP/NP) product will mean in practice that all submissions, including EU PSUR Single Assessment submissions, must be provided for each eCTD separately in accordance with the chosen dossier structure (for details see [Section 4.5](#)).

Also note that a single eCTD cannot cover a product authorised/applied for within an MRP/DCP in some MSs and within a NP in other MSs. Also, a single eCTD lifecycle cannot cover a product that is nationally authorised in different MS. I.e, you can never mix an MRP/DCP and an NP product in the same eCTD application nor different NP products.

## 2.3 Transitional Arrangements

The specifications mentioned in Section 2.2 above are likely subject to changes and are likely to affect both eCTD building tools and the applicant's internal business processes as well as the agencies' review tools and processes. Once a new eCTD specification and/or the related validation criteria has been approved, eCTD building tools will need to be updated accordingly and specific transitional guidance will be provided on each occasion. However, minor changes that do not change the Document Type Definition (DTD) of the eCTD specification, but only the text may also be published and would then not affect any tools, but rather the handling or business process of the eCTD lifecycle.

Please note that it should not be necessary to reformat and resubmit previously submitted applications to reflect such changes.

## 2.4 Change to eCTD Format

eCTD is the mandatory format for all electronic submissions referred to in 2.1. If the product dossier was earlier handled in paper or NeeS format, the next upcoming submission needs to be submitted in eCTD format. This also includes submissions concerning other ongoing regulatory activities related to that eCTD application (e.g. responses to questions to ongoing variations), in which case, it will obviously not be possible to use the related sequence attribute (see section 2.9.5.) correctly since the start of the regulatory activity is not present as an eCTD sequence to refer to and therefore the validation criterion 14 BP2 will not be met. This should be reflected in the cover letter.

If the dossier has already been provided in NeeS format, the applicant should submit the new data in eCTD format starting the lifecycle in accordance with eCTD specifications. The first submission in eCTD format will normally be sequence 0000, even if sequential numbers were used for the NeeS format. For clarity, the cover letter should always explicitly state that the submission involves a switch to eCTD format. As the documents already exist in an electronic format, it would be preferable to first re-send the currently valid documents, especially module 3, as a baseline eCTD dossier in sequence number 0000 and then the first new regulatory activity as 0001. Please see [Section 2.12](#) for further information on the content of baseline applications and the acceptability of scanned documents.

Any historical sequences (e.g. sent to new CMSs within an RUP) should not be technically validated by the agencies receiving them for the first time, for further details see the '[CMDh Best Practice Guide on the use of eCTD in the MRP/DCP](#)'. However, if there are problems with loading or reading the "old" files, the applicant should assist in solving the technical problems on the sequences to facilitate their use in the "new" NCA, for example due to mistakes in transmission or creating the submission or problems with the XML, which can be resolved without affecting future lifecycle.

In any case, a tracking table is essential to understand the sequencing of your eCTD submission and should be included in all submissions in all procedure types (please refer to [Section 3.2.3](#)).

A baseline submission is recommended at the time of changing to eCTD to give the agencies access to all or at least part of the previously submitted documentation within the eCTD lifecycle even if this is not mandatory (see [Section 2.12](#)).

## 2.5 General Submission Considerations

### 2.5.1 Document Granularity

Submissions are a collection of documents and each document should be provided as a separate file. The detailed structure of the eCTD should conform to the [ICH Granularity Document](#) and EU M1 specification. Careful consideration is needed when deciding the level of Module 3 granularity (please refer to [Annex 3, Section 3.1](#)).

### 2.5.2 File Naming

The eCTD file naming conventions described in the ICH M2 eCTD Specification and EU Module 1 eCTD Specification are highly recommended, as best practice. If an applicant wishes to submit multiple files in one section, where only one highly recommended name is available, this can be achieved by using a suffix to the filename, such as using the file name-*var*.pdf convention as described in the EU Module 1 eCTD Specification (e.g. pharmaceutical-development-*container*.pdf). The variable part of the name must not contain “illegal” characters (e.g. %, /, <).

File names, including the extension, must not exceed 64 characters. Also, the folder names must not exceed 64 characters and the total file folder path length must not exceed 180 characters. Counting starts from the first digit of the sequence number in the sequence number folder name.

For further guidance on file naming, please refer to the “File-Folder Structure & Names” work sheet included in the current [validation criteria](#)

### 2.5.3 Placement of Documents

Guidance on the placement of documents within the eCTD structure can be found in [Notice to Applicants Volume 2B](#) and/or in the [EMA post-authorisation guidance](#) for centralised applications.

In the submission structure, leaves should typically be placed at the lowest level of the CTD structure, although there are some exceptions to this guidance, for example, in 32p4-contr-excip, where the files excipients.pdf, excipients-human-animal-var.pdf or novel-excipients-var.pdf can be placed alongside folders containing details of other excipients. The lowest levels of the CTD structure (including node-extensions) must contain at least one leaf, although this should normally be managed automatically by the eCTD building tool.

- m3-quality
  - m3-2-body-of-data
    - m3-2-s-drug-substance [manufacturer: manuf1] [substance: subst1]
      - m3-2-s-2-manufacture
        - m3-2-s-2-1-manufacturer
          - [3.2.S.2.1 Manufacturer](#) [new]

Lowest level of CTD structure

Every leaf must have a value for the ‘title’ attribute.

## 2.6 Correspondence

The eCTD is designed to ensure that users have a current view of the information submitted in the appropriate place of the dossier at all times. Therefore, formal responses to questions should always be submitted in eCTD format, as well as any correspondence that relates directly to the content of the dossier. However, there might be some correspondence that are requested to take part outside the eCTD and if so, this is clearly stated in other guidance documents (e.g. in the ‘CMDh BPG on the use of eCTD in MRP and DCP’ at the [CMDh website](#)).

## 2.7 Paper Requirements

Some NCAs may still require paper copies of some documents in addition to the eCTD; refer to the CMDh guidance '[Requirements on submissions for New Applications within MRP, DCP or National procedures](#)' '[Requirements on submissions for Variations and Renewals within MRP and National procedures](#)' for further details.

## 2.8 Hardware

NCAs and the EMA will not accept any hardware (laptops, desktops, external hard drives etc.) from applicants in connection with the submission of information in electronic format. The electronic information should be directly readable and usable on NCAs' and EMA's hardware and software.

## 2.9 General Technical eCTD Information

### 2.9.1 Identifier for Applications

To help enable archiving the sequence with the correct dossier (eCTD lifecycle), applicants must state a unique identification of the dossier in the form of a UUID. The identifier must be defined with the first sequence of a new dossier (or the first sequence using EU M1 version 3.0 or later), and it must be consistent throughout the eCTD lifecycle. The identifier must not be changed except in certain scenarios, see [Section 2.11.3](#).

The UUID is a 32 digit (8+4+4+4+12) hexadecimal string, for example: "123e4567-e89b-12d3-a456-426655440000". When defining a UUID the string should be decided at random. The string should contain no information referring to any other metadata. This is to ensure consistency even if the relevant metadata should change. The chance of two different dossiers having the same UUID is next to none if the UUIDs are truly defined at random.

### 2.9.2 File Formats

According to the EU eCTD validation criteria only pdf documents can be provided within the eCTD sequences. In general terms most documents included in electronic submissions should be provided in PDF format (see next section on the use of PDF file versions). Files that might be requested by NCAs or the EMA in MS Word format should *not* be included in the eCTD structure (refer to [Section 2.9.10](#)) but be provided in the working documents folder.

Further detailed guidance on file formats can be found in the ICH eCTD specification document and EU Module 1 specification.

### 2.9.3 Portable Document Format (PDF)

Portable Document Format (PDF) is an ISO standard (ISO 19005-1:2005 Document management – Electronic document file format for long-term preservation – Part 1: Use of PDF 1.4 (PDF/A-1) and ISO 32000-1:2008 Document management – Portable document format – Part 1: PDF 1.7). Although created by Adobe Systems Incorporated, there are several alternative suppliers of PDF software. Applicants need to check that their PDF documents meet the following key requirements:

- PDF version 1.4, 1.5, 1.6 or 1.7 should normally be used, except where there is an EU or agency specific requirement for another version.
- PDF/A format is recommended where possible.
- PDF 1.3 or earlier versions are not acceptable for technical reasons. No exceptions will be made. For example, if a literature reference is received in PDF 1.3 or earlier, then the applicant must convert it to PDF 1.4, 1.5, 1.6 or 1.7, either electronically or by scanning.
- Applicants are requested to ensure that all submissions contain the maximum amount of text searchable content to facilitate the assessment of the eCTD content. PDF documents should therefore, wherever possible, be produced from a text source such as MS Word. If scanning is unavoidable, it should normally include OCR. However, there are some documents where the scanned document would not be expected to include OCR, i.e.:
  - Any GMP certificate
  - Any certificate of analysis
  - Any manufacturer's licences
  - Any certificate of suitability
  - Any Manufacturing Authorisation

- Any document written in a foreign language where a translation is provided in English (however, the translation should be text searchable)
- Any literature references sourced from journals, periodicals and books (except when these are used in a bibliographic application to support the main claims of the application).
- The blank CRF in a Clinical Study Report
- Patient data listings (when supplied)
- CRFs (when supplied)
- Any page with a signature that does not contain other information key to the understanding of the submission (However, applicants should consider providing signatures on pages separated from key text pages in reports, overviews, etc.)

Additionally, the following requirements should be taken into consideration:

- Different requirements apply in the EU to NCAs and the EMA for signatures on application forms and cover letters. – For details refer to [Section 2.10.4](#). Make sure that scanned cover letters are text searchable.
- The fonts used in the PDF should be embedded in the PDF where possible.
- Rendition to PDF should preferably create documents which are "tagged".
- Use 'Fast Web View' where possible to ensure optimum performance of the review system.
- PDFs should not be included in the eCTD as a PDF Portfolio.

Additional details on PDF, including those relating to the good presentation of tables, can be found in the [ICH eCTD Specification](#), Appendix 7. Refer also to the [ICH M2 recommendations](#).

## 2.9.4 Sequence Numbers

Sequence numbers are used to differentiate between different submissions of the same application over the lifecycle of the product. The review tools being used by most NCAs and the EMA can handle sequences submitted out of numerical order, i.e. 0003 submitted after 0004. This can occur when the preparation of a sequence is delayed. However, it is recommended that sequence numbers follow the order of submission of the sequences, as sometimes a higher sequence is technically related to the previous – not yet submitted – sequence which will result in technical invalidation. A Sequence Tracking Table should always be included in section 1.0 in every submission for all procedures. For details see [Section 3.2.3.2](#).

The initial eCTD lifecycle submission should normally have the sequence number of 0000, even if sequential numbers were already used for a NeeS format of the same product. If applicants consider that there are good reasons to use another number, they should explain this in the cover letter.

When additional information is submitted in response to questions or when information in a previously submitted sequence is modified in any way, the sequence number of the submission will advance accordingly, e.g. 0001, 0002, etc. Only in the case of a technically invalid submission, at request from or agreement with the EMA (CP) or an NCA (MRP/DCP/NP), a sequence can be replaced with another using the same number (e.g. the initial sequence "0000" will be replaced by another "0000"). The new sequence should be sent to all concerned authorities. No new documents may be included in these cases, but only technical problems should be fixed. The reason for resending the same sequence must be clearly stated in a comment in the delivery file (CESP, working documents or separate note in case of CD/DVD submissions). For submissions to the EMA it is mandatory to use the eSubmission Gateway / Web Client and no additional comment is required. If the eCTD needs to be updated due to content/regulatory validation, any revised content should be provided with a new sequence number and the changes clarified in the cover letter.

## 2.9.5 Related Sequence

All submissions need to contain a value for "related sequence". If the submission unit type is 'initial' or 'reformat' then the related-sequence attribute must have a value equal to the current sequence.

If the submission unit type is not 'initial' or 'reformat' then the entry for related sequence should be populated with the number of the sequence that started the regulatory activity.

**Table 1 : Example of a PSUSA**

Sequence number	Submission Description	Submission Type	Related Sequence	Submission Unit
0008	PSUR single assessment procedure	psusa	0008	initial

0009	Validation update	psusa	0008	validation-response
0010	Comments on Assessment Report	psusa	0008	response

**Table 2 : Example of a Referral for CAPs**

Sequence number	Submission Description	Submission Type	Related Sequence	Submission Unit
0008	Responses to LoQ	referral	none	initial
0009	Comments on Assessment Report	referral	0008	validation-response
0010	Responses to LoOI	referral	0008	response

**Table 3 : Example of a Referral for NAPs**

Sequence number	Submission Description	Submission Type	Related Sequence	Submission Unit
0008	Responses to LoQ	referral	none	initial
0009	Comments on Assessment Report	referral	0008	validation-response
0010	Responses to LoOI	referral	0008	response

It is expected that there is just one Related Sequence, but there are occasions where more than one Related Sequence should be provided as for example:

- 1) When there are two PAM related sequences (sequence 0005 and sequence 0006) and a single response (sequence 0007) is produced that relates to both PAM related sequences.
- 2) When there are two parallel variations (sequence 0002 and sequence 0003) and there is a sequence (0004) that brings the label up to date by including the changes made in both variations.

On these occasions multiple related sequences are used, but if a subsequent sequence relates to only one of the original regulatory activities, then only the related sequence for that particular regulatory activity should be used.

If the related sequences refer to both a single and grouped variation, the metadata should state 'grouped' as being the highest level of regulatory activity.

Further examples are provided in the EU eCTD M1 Specification document.

## 2.9.6 Leaf Lifecycle Operation Attributes

The leaf lifecycle operation attributes, as stated in the eCTD Specifications, are 'new', 'append', 'replace' and 'delete'. However, in the EU, it is recommended that applicants avoid the use of 'append' due to the potential for increased lifecycle complexity.

Lifecycle operations where the leaf targeted by the modified file is in a different CTD section are not allowed. This applies across all the modules of the CTD and is not specific to either the regional or ICH Modules.

Where elements are repeatable, both the element itself and the attributes that define a different position in the table of contents must be identical when modifying a leaf element in a previous sequence. Where node extensions are allowed, the node extension title element should be identical when modifying a leaf element in a previous sequence. However, it is acceptable occasionally if inconsistencies have been introduced in the past. In those cases, it is recommended to use the most recent version of the title attribute.

**Table 4 : Repeatable Elements and Attributes that Define Different Sections**

<b>Element</b>	<b>Attributes also identifying a section</b>
<b>Module 1</b>	
m1-0-cover	country
m1-2-form	country
m1-3-1-spc-label-pl	country xml:lang type
m1-3-2-mockup	country
m1-3-3-specimen	country
m1-3-4-consultation	country
m1-3-5-approved	country
m1-responses	country
m1-additional-data	country
<b>Module 2</b>	
m2-3-s-drug-substance	substance manufacturer
m2-3-p-drug-product	product-name dosageform manufacturer
m2-7-3-summary-of-clinical-efficacy	indication
<b>Module 3</b>	
m3-2-s-drug-substance	substance manufacturer
m3-2-p-drug-product	product-name dosageform manufacturer
<b>Module 5</b>	
m5-3-5-reports-of-efficacy-and-safety-studies	indication

The only exception to this is the change in agency name at the EMA; leaves with the specific country attribute 'ema' or 'emea' should be considered equivalent and lifecycle must be allowed between them.

Note, in the eCTD XML, sections, leaves and node extensions may have other attributes, such as xml:lang, font-library, version, keywords, ID etc. These attributes, if supplied, do not result in a new logical section in the eCTD table of contents and therefore lifecycle between leaves where these attributes are not identical is allowed; only the attributes in the table above define different eCTD sections.

**Examples:**

**Pass/Fail**

- A leaf to be submitted in m4-2-2-5 in Sequence 0012 cannot replace/delete a leaf submitted in m4-2-2-2 of Sequence 0010.
- A leaf in m1-responses cannot modify content in m1-0-cover (different section)
- A leaf in m3-2-s-drug-substance [manufacturer: abcd] [substance: xyz] cannot modify content in m3-2-s-drug-substance [manufacturer: other] [substance: xyz], or any section other than the specific manufacturer 'abcd' and substance 'xyz' section.
- A leaf in m1-0-cover with the specific attribute 'dk' cannot modify a leaf in m1-0-cover with a specific attribute of anything other than 'dk'.
- A leaf in m1-3-pi with the specific attributes <pi-doc xml:lang="en" type="combined" country="ema"> cannot modify a leaf with different attributes, such as <pi-doc xml:lang="fr" type="other" country="ema">.

**Best Practice Criteria**

- A leaf in a node extension should only be modified by a leaf in the same equivalent node extension in a subsequent sequence. For example, a leaf in a node extension in m5-3-5-1 of sequence 0000 with a <title> attribute 'Study 1234' should not be modified by a leaf in a different node extension with a <title> attribute 'Study 1234 – update' in sequence 0001 – the append/replace/delete leaf ideally needs to be in an identical node extension in 0001 ('Study 1234' in the same location, m5-3-5-1).

If the applicant places content in the wrong CTD section and needs to correct this (either upon request from the agency receiving the eCTD or because they wish to correct the mistake) then the way to do this is to create two leaf elements in a subsequent sequence. The first leaf will use the “delete” leaf operation to remove from view the incorrectly placed content. The second leaf will usually use the “new” leaf operation to locate the content in the correct CTD section. The file does not need to be resubmitted, the “new” leaf can use the xlink:href attribute to point to the originally submitted content in the earlier sequence.

However, applicants cannot submit a dossier using the old specification and DTD. Therefore, deleting the content in the old section will involve lifecycle from the changed section (for example, m1-additional-data) deleting content in the equivalent section with the original name (in this example, m1-additional). This may not be possible in all eCTD building tools, and if so, applicants are advised to leave the original content as it is, but to start providing new or replacement content in the revised section.

**Note:** Lifecycle operations across eCTD applications are not allowed.

## 2.9.7 Bookmarks and Hypertext Links

Navigation through an electronic submission is greatly enhanced by the appropriate use of bookmarks and hypertext links. ICH Q&A number 53 states, “It is expected that any document that has a Table of Contents (TOC) will have bookmarks (see the eCTD specification for details). Documents without TOCs should have bookmarks included where it aids in the navigation around the document content. For example, a 4 pages long document that is summarising findings could require bookmarks to aid navigation. However, a 300 pages long file containing a single data listing might not require bookmarks as there is no further internal structure. Please consult regional guidance documents for further details.”

In general terms, bookmarks and hyperlinks should be used to aid navigation. The overuse of hyperlinks may confuse rather than help assessors and may cause problems later in lifecycle management. However, hyperlinks back to previously submitted documents are welcome if pointing to the correct location.

Additional details on creating bookmarks and hypertext links in PDF documents can be found in the [ICH eCTD Specification](#), Appendix 7.

With the current version of the eCTD specification, it is not possible to cross refer from one eCTD application to another.

## 2.9.8 Node Extensions

Node extensions may be used where additional navigation in the XML backbone is required. The primary place where they are used is in Module 5 where a node extension for each study is useful to group together the multiple leaves that make up the study and its modular appendices, in a study specific folder. Also, it could be useful to differentiate reports associated with a different dosing regimen for the same indication. For Module 4 when submitting reports consisting of multiple pdf files, node extensions can also be useful with an associated subfolder. In Module 1, node extensions should be included to differentiate the responses at different stages of the lifecycle. For further details on responses, see [Section 3.2.6](#). Currently, additional folders in m1-responses are not allowed and therefore, the use of an additional folder in combination with a node extension is not possible.

Please note, the use of node extensions should be limited to those areas where it is critical and consideration should be given regarding the impact of the view for the reviewer since the inconsistent use of node extensions can lead to unanticipated effects in the cumulative view of a submission.

When node-extensions are used the ‘title’ attribute in the XML backbone must have a value.

## 2.9.9 Extensible Mark-up Language (XML)

XML is the format for the backbone files for the eCTD. Details on XML can be found in the [ICH eCTD Specification](#) Document, Appendix 7. Initiatives on the use of XML structured information are supported by NCAs and the EMA for electronic application forms (eAFs). Please refer to [EMA eSubmission website](#) for further details.


## 2.9.10 Other File Formats

Other file formats such as MS Word formats may be required by some NCAs or the EMA *in addition* to the PDF requirement of the eCTD, especially for the provision of product information documents or the Module 2 documents. Please refer to the [CMDh website](#) for further details on NCAs requirements.

The files referred to above should not be added as leaf elements within the eCTD structure. When submitted with an eCTD, they should always be provided in a separate folder called “xxxx-workingdocuments” on the same submission zip package or on the same CD/DVD containing the eCTD, where the number (xxxx) matches the number of the eCTD sequence being submitted.

For PMF certification submissions the ePMF should be provided within the working documents folder. The folder should be called “xxxx-workingdocuments” as for all other documents. For more information please refer to the guidance on [PMF eCTD Guidance document](#).

If working documents for more than one NCA are submitted on the same submission, sub folders with the country code should be used.



**Figure 1 : Sample of folder structure**

For information on translations being provided outside the eCTD, refer to [Section 3.2.5](#)

If, at any stage in a procedure, an email or EudraLink message is used to send information, this does not change the format requirement. The subject line of the message should always include as a minimum the product name and procedure number for identification purposes. The EMA does not accept submissions sent via email or EudraLink.

### 2.9.11 Technical Validation of eCTD Submissions

The technical validation of an eCTD is a separate activity compared to the content validation of a submission and takes place irrespective of the type of the submission. NCAs and the EMA have adopted a [common set of technical validation criteria](#) against which all eCTDs can be checked using eCTD review and validation tools. It is strongly recommended that all sequences are checked and found technically valid according to the published validation criteria.

Two categories of validation rules apply: “Pass/Fail”, and “Best Practice”:

#### Pass/Fail Criteria

This is a set of technical validation criteria that can either be passed or failed. eCTDs that fail to meet one or more of these criteria will be rejected and a resubmission of the same sequence number will be required. All Centralised Procedure (CP) eCTD submissions via the eSubmission Gateway / Web Client to the EMA are automatically run through a full technical eCTD validation and an automated ‘success’ or ‘failure’ acknowledgement is sent to the applicant/MAH. eCTD submissions for PSURs authorised via MRP/DCP/NP are checked using a ‘tolerant’ eCTD validation checking only the structure of the eCTD submission. This means that even if your submission has been successfully submitted via the eSubmission Gateway/Web Client, a technical validation issue can be found by an NCA at a later stage but will be coordinated by the EMA in that case.

#### Best Practice Criteria

These are validation criteria that are considered good practice to facilitate the review of an eCTD.

The applicant should make every effort to address these areas before the eCTD is submitted. eCTDs that fail to meet one or more of these criteria will still be accepted by the receiving agency/agencies during technical validation and it is possible that agencies may not even check these criteria during technical validation.



**Note: These criteria cannot test the correctness of the metadata. Therefore, applicants need to make sure that all metadata are filled in correctly.**

Errors found during the content validation e.g. mistakes in an application form to be corrected, should be resolved through the submission of a new eCTD sequence using the next sequence number. These errors, which are content errors, must never be resolved by resubmitting an existing sequence by re-using the same sequence number.

An exception to this would be if the *envelope* is incorrect and it is requested by an agency to be corrected and resubmitted with the same sequence number. In such scenarios, the updated sequence (same sequence number) should only be submitted to the requesting agency. Nothing else should be changed in the sequence and it should be clear from the delivery information that this is a re-submission of the same sequence number with just an envelope correction and that the former submitted sequence number should be exchanged to this update (i.e. as the handling of a technically invalid sequence).

If historical sequences that have already been submitted in another MS in the EU are supplied to a new NCA, the receiving NCA should not technically validate these sequences, as they have already been accepted when originally submitted. This could be the case where, for example, in repeat use, switching from parallel national to comprehensive model, supply of eCTD sequences to an NCA where this same submission had been formerly submitted in NeeS or paper format but in eCTD format to other NCAs. However, if there are problems with loading or reading the newly submitted files, the applicant should assist in solving the technical problems on the sequences to facilitate their use in the "new" NCA.

## **2.10 Other Technical Information**

### **2.10.1 Protection against Malware**

The applicant is responsible for checking the submission for malware such as viruses. Checking should be performed with an up-to-date virus checker. After receipt at NCAs and the EMA, a similar internal virus check will be performed. If a virus is detected it will constitute grounds for technical invalidation of the submission.

### **2.10.2 Security Settings**

Submission or file level security is not permitted. If one-time security settings or password protection of electronic submissions are used this could constitute grounds for the rejection of the submission.

There must be no security setting to open any individual file. This includes passwords, certificate security, adobe policy server settings, etc.

Furthermore, there must be no security settings applied to any individual file, except for files in Modules 1.0, 1.2, 3.3, 4.3 and 5.4. This means that security settings in for example Adobe Acrobat, all "restrictions" should normally be "allowed" when viewing the Document Preferences > Security settings. If for some reasons this is not possible for some documents, e.g. for digitally signed documents, as a minimum printing and content copying need to be allowed.

### **2.10.3 Signatures**

Electronic signatures are regulated in EU by *Regulation (EU) No 910/2014 of the European Parliament and of the council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC*. For applications of Marketing Authorisations including post-authorisation submissions, most NCAs and EMA do not require wet or digitally signed cover letters or application forms if submitted through a portal (e.g. CESP and EMA Gateway) with logon credentials. However, some NCAs still require additional signatures and might accept wet signatures, scanned signatures and/or electronic signatures as specified in the CMDh document '[Requirements on submissions for New Applications within MRP, DCP or National procedures](#)' and '[Requirements on submissions for Variations and Renewals within MRP and National procedures](#)'.

For EMA submissions, in general qualified and advanced electronic signatures as per the European Commission eIDAS regulation (Regulation (EU) No 910/2014) are accepted.

## 2.11 Technical Baseline Applications

A baseline submission is a compiled submission of the current status of the dossier, i.e. resubmission of currently valid documents that have already been provided to an agency but in another format. The sections provided to make up a baseline can be defined by the applicant, but any omissions should not render the submitted content misleading. A baseline would typically consist of the Module 3 documents that tend to change over time during the lifecycle of the product.

It is highly recommended, but not mandatory, to use a baseline as a start of an eCTD when changing from paper or NeeS and to provide as much content as possible in the eCTD. The baseline would preferably consist of high-quality electronic source documents, but good quality scanned images would also be acceptable in these cases, preferably with Optical Character Recognition (OCR) to facilitate text searching.

It should be clearly stated in the cover letter of the “baseline eCTD sequence” that the content of the previously submitted dossier has not been changed, only the format. There is no need for the NCAs or EMA to assess baseline submissions and hyperlinks between documents are therefore not needed. The submission type *reformat* should be used in the envelope for the baseline sequence.

### 2.11.1 Baselines Starting as Sequence 0000

The baseline should normally be submitted as sequence 0000 but could in some justified situations also be submitted at a later stage (see Section 2.12.2 below). The baseline should always be a separate submission and should never include new applications. The first new regulatory activity, e.g. the next variation, in eCTD format should then be submitted as sequence 0001, see table below.

**Table 5 : Example for starting an eCTD with a baseline sequence**

Sequence number	Submission Description	Submission Type	Related Sequence	Submission Unit
0000	Baseline of Module 3	none	0000	reformat
0001	Variation for new indication of COPD	var-type2	0001	initial
0002	Response to Questions	var-type2	0001	response
0003	Variation to shelf life	var-type1b	0003	initial
0004	Extension for 8mg tablet	extension	0004	initial

### 2.11.2 Baselines Starting Later in Lifecycle

A baseline can also be submitted later in the lifecycle. If documents have already been provided in previous submissions in the sections now covered by the baseline, these should not be re-submitted. Instead, the remaining incomplete sections should be filled up with earlier dossier content (paper or NeeS), now provided in eCTD format for the first time.

It is possible to use multiple sequences to submit a baseline, e.g. one sequence for the baseline for Modules 4 and 5 followed later by one sequence for the baseline for Module 3. The submission type ‘reformat’ should be used in each case. An example is given below.

**Table 6 : Example for starting an eCTD with regulatory activity sequence**

Sequence number	Submission Description	Submission Type	Related Sequence	Submission Unit
0000	Variation concerning Modules 4 & 5	var-type2	0000	initial
0001	Variation for new indication of COPD	var-type2	0001	initial
0002	Response to Questions	var-type2	0000	response
0003	Baseline of Module 3	none	0003	reformat
0004	Extension for 8mg tablet	extension	0004	initial

In cases where a product, nationally approved in more than one EU country, becomes an MRP product through a referral, it is quite likely that the eCTD dossiers submitted nationally are incompatible and thus cannot be used to continue the MRP dossier. The dossier might then have to start anew, from sequence 0000 and be compiled in line with the [CMDh Best Practice Guide on the use of eCTD in the MRP/DCP](#). In such cases, a baseline submission might be justified in order to give all the CMSs access to the previously submitted documentation. For details on how to transfer existing eCTD lifecycle from one procedure to another (e.g. at the end of an Article 30), see Section 2.12.3 below.

For eCTD dossiers created with old tools and/or in accordance with technical criteria which are now outdated, a baseline can be submitted in order to “clean up” the dossier from any technical issues that would cause problems. However, the applicant should first ensure that there are no other ways of rectifying these technical issues so that this option is not used unless absolutely necessary.

The technical baseline application can also be used by applicants to switch from one eCTD sequence per strength to one eCTD sequence covering multiple strengths (see Section 2.12.3 below). The switch from one approach to another should normally only be allowed once during the lifecycle and must be agreed by the relevant authority.

### **2.11.3 Re-Baselining a Broken eCTD Lifecycle**

One of the principles of eCTD is that with the use of the operation attributes, it is possible to manage the lifecycle of a product and generate a view of the “current dossier”.

However, in certain cases, the lifecycle at the side of the applicant may be broken.

This situation can occur in cases such as:

- An MA is transferred to another MAH who is unable to import any existing eCTD sequences into its building tool
- An applicant switches to a new publishing tool and is unable to import their submitted sequences
- An applicant is working with a lifecycle where previously submitted sequences are actually technically invalid, but were not technically validated at the time by the receiving agency

The problem with all of these situations is that the applicant cannot continue with the existing lifecycle of the product. Any subsequent submission (sequence) for the product where previously submitted content is changed and needs to be referred to (using the operation attributes replace, or delete) cannot be built in the tool, or, if built, would be invalid. This is because it is impossible to create the link back to the original submitted documentation, because it no longer resides in the eCTD building tool.

In these first three examples, the preferred situation would be that the previously submitted sequences are imported in the new tool and the lifecycle of the product will continue. However, this might not be possible, due to technical issues in uploading previous sequences into a different tool, or particularly when the previous sequences were invalid. If the lifecycle re-starts a new UUID for the application is required.

In addition, in exceptional cases, there may be a benefit to both the applicant and to the agency if the current lifecycle is archived in some way and re-started. For example:

- An applicant has chosen in the past to submit more eCTD applications than needed under current guidelines, for example, one for each strength of a product
- An applicant has used the parallel national model in MRP/DCP and needs to switch to the comprehensive model
- At the end of an Article 30 procedure, the applicant is switching from national eCTD in one or more MS to a comprehensive eCTD for the new MRP

To ensure that the lifecycle of the product is correctly maintained going forward, it is proposed that in these exceptional circumstances, and with prior agreement between the MA holder and the receiving NCA (national procedures), the RMS (MRP/DCP) or EMA (centralised procedures), applicants are allowed to resubmit the current registered dossier as a baseline consisting of all valid documents as seen in “current view”, leaving the existing sequences in place, but essentially resubmitting the content in a new eCTD application. Also, in these cases a new UUID for the application is required. It is strongly recommended to finalize ongoing regulatory activities before submitting the baseline.

In the cover letter the applicant must provide details of why the lifecycle is broken and state that a baseline eCTD sequence is being submitted in order to restart the lifecycle.

- A new UUID needs to be assigned to the application.
- The submission type would be “none”
- The submission unit type would be “reformat”.
- The operation attributes of the leaves would be all “new”.
- The sequence number of the submission would normally be restarted at 0000 and not continued from the previous lifecycle, since continuation of existing numbering could lead to complex lifecycle issues.

However, when compiling (merging) several eCTDs built per strength and/or dosage form of a product into only one combined eCTD for that product, normally one of the existing eCTD lifecycles would be kept and be completed with the missing documents from the current view of the other strengths and/or dosage form eCTDs to give the complete current dossier. In those cases, the assigned UUID of the maintained eCTD (the chosen strength or dosage form built upon) will also serve as UUID for the future (merged) lifecycle. The strategy for merging of eCTDs should be agreed with the relevant authorities in advance.

### **Re-baselining where the previously submitted sequences cannot be used in the new lifecycle and must be archived**

*For the agency, the former submitted sequences have to be handled as “history”, and the new set of sequences would need another identifier to be set by the authority to differentiate them from this previous lifecycle. The lifecycle will begin from scratch again from the time of the baseline submission with a new UUID in each sequence built with EU eCTD m1 v3.0 or later. In an MRP, there is no need to mention the previous (archived) sequences in the tracking table, so the new tracking table should only refer to the re-established lifecycle.*

#### **Scenario 1 – previously submitted sequences archived, new eCTD lifecycle started**

Applicant X has submitted sequences:

0000 Initial application  
0001 Validation update  
0002 Day xx response  
0003 Day yy response  
0004 Variation 001

\*\* Problem occurs in continuing lifecycle, **see examples below**

0005 → 0000 - Next submission

0005 is not submitted. Instead, 0000 - 0004 are archived, and a new eCTD is started at 0000.

#### Examples for this scenario:

\*\* MA is transferred, previous sequences 0000-0004 cannot be imported into a tool by the new holder.

\*\* Applicant changes their eCTD Building tool, previous sequences will not import into the new tool

\*\* Previous sequences 0000-0004 were technically invalid according to the specification at the time, but were accepted by the agency because eCTD checking was not yet established

\*\* Sequences 0000-0004 were “not mutual” (parallel national) – not all countries in the procedure may have received all of them with the same sequence number

### **Re-baselining where the previously submitted sequences in at least one MS can be used as existing lifecycle**

*In the case that previous lifecycle can be continued, but submitted in additional member states, then there would be no need to change the identifier or UUID. In an MRP, the tracking table should indicate which member states originally had the sequences, and which member states are now getting them as lifecycle history.*

#### **Scenario 2 – previously submitted sequences valid, lifecycle continued**

Applicant X has submitted sequences:

0000 Initial application  
0001 Validation update  
0002 Day xx response  
0003 Day yy response

0004 Variation 001

\*\* Problem occurs in continuing lifecycle without making changes to the scope of the eCTD application, **examples below**

0005 = Next submission

The original sequences are maintained, but a “new” eCTD lifecycle is started at 0005, where more countries receive the lifecycle.

#### Examples for this scenario:

\*\* Sequences 0000-0004 were “not mutual” (parallel national) – all countries in the procedure have received all of the sequences as individual national sequences with the same sequence number

\*\* Earlier sequences 0000-0004 referred to only one strength or dosage form, but the new lifecycle will cover more multiple strengths/forms. Note there is no need to alter the metadata from the previously submitted sequences, the additional strengths / dosage forms can be added in subsequent sequences.

\*\* Earlier sequences 0000-0004 were used in national procedure prior to an Article 30 procedure, but can be re-purposed for the new MRP

## **2.12 Procedure for Sending Electronic Information**

### **2.12.1 Portals/Gateways**

#### **Common European Submission Portal - CESP**

Submission via CESP, is mandatory for MRP/DCP. For details on NCA requirements on submissions, please refer to the ‘Requirements on submissions for New Applications within MRP, DCP or National procedures’ at the [CMDh website](#). Any required paper documentation should be dispatched in parallel at the same time as the CESP submission.

When using CESP, the delivery file XML details should be based on the eCTD envelope metadata.

For worksharing procedure or grouped variation covering multiple MAs submitted via CESP, all eCTD submissions for the products concerned should be provided in separate folders within one submitted zip file. If there are MAs not approved in all countries concerned by the procedure, this could be clarified in the CESP delivery file (in “Comments”).

If the procedure is MRP, tick the RMS for the Grouping/Worksharing procedure. Tick the dummy RMS “ZZ” if you intend to submit something only to one or more CMS agency (e.g. when a correction or a nationally required document is sent to a CMS only).

If, for whatever reason, multiple submissions are required for the same procedure (e.g. for duplicate dossiers having different MAHs), this should be clarified in the same way as above, in each CESP delivery file.

#### **EMA eSubmission Gateway**

Submission via the EMA Gateway is mandatory for Centralised Procedure and for a number of other EMA coordinated procedures containing Nationally Authorised Products, for example, but not limited to EMA led worksharing variations, Signal Detection (EPITT) procedures, PASS107, and EU PSUR Single Assessment Procedure. For such procedures, the submissions for NAPs should only be made to the EMA via eSubmission Gateway (see the [eSubmission Gateway website](#) for details) and there should be no duplicate submissions sent directly to the NCAs. Information identifying the submission should be included in the XML delivery file.

All PSUR submissions within all procedure types, including non-EU single assessment PSURs for Member States, should be submitted to the PSUR Repository via the EMA eSubmission Gateway. Please refer to the [eSubmission PSUR Repository website](#).

Referral procedures, other than CMDh referrals Dir 2001/83/EC art 29(1) and Reg 1234/2008 art 13, should also be submitted via the EMA Submission Gateway with details in the delivery file.

## **National Gateways**

There are also national portals in some countries, mandatory or optional, see the '[Requirements on submissions for New Applications within MRP, DCP or National procedures](#)' and '[Requirements on submissions for Variations and Renewals within MRP and National procedures](#)' and individual NCA websites for further details.

### **2.12.2 CD / DVD**

By exception, CD/DVD submissions might still be accepted by some national competent authorities for pure National Medicinal Products. Refer to the documents '[Requirements on submissions for New Applications within MRP, DCP or National procedures](#)' and '[Requirements on submissions for Variations and Renewals within MRP and National procedures](#)'..

Zipped files should not be used when sending CDs or DVDs.

- Each CD/DVD submitted should include the applicant's name, the product name, the procedure number (if known), the sequence number, the number of the media unit (e.g. 1(5), 2(5) etc.) and the submission type (as stated in the envelope) clearly printed on the media.

The details of the number of copies of CD/DVD to be submitted (if accepted at all) are published in the documents '[New Applications within MRP and National procedures](#)' and '[Requirements on submissions for Variations and Renewals within MRP and National procedures](#)' at the [CMDh website](#).

The EMA does not accept CDs / DVDs or any other external media.

### **2.12.4 EudraLink / e-Mail (where applicable)**

EudraLink and e-mail should not be used for eCTD submissions.

However, it may be used as a submission channel to share eCTD sequences with prior agreement from or at the request of the receiving agency. Sequences shared via Eudralink/e-mail should in these specific cases subsequent be submitted via the relevant formal process, e.g. CESP.

If EudraLink is used for sending an eCTD sequence, the entire sequence has to be provided as a zip file (.zip).

Please also note there is a size limit, refer to the EudraLink User Guide for further details.

When using EudraLink, it is strongly recommended that the expiry date is set to the maximum (90 days) to ensure that it can be opened during the process at the receiving authority.

## 3. Module Specific Information

### 3.1 General Information

The following subfolders should be used to organise the files for each module in a submission: *m1*, *m2*, *m3*, *m4*, and *m5* following the principles set out for the CTD in [Notice to Applicants, Volume 2B](#). There is also a subfolder *util* to organise eCTD technical files in the submission. If a module is not appropriate for a particular submission it should be omitted. Empty subfolders should not be included.

Each document should be provided as an individual PDF file, except those specifically requested in a different format.

A single eCTD application can cover multiple drug substances (e.g. in case of fixed combination products), multiple manufacturing sites, multiple medicinal products based on one invented name (different dosage forms or strengths). Careful planning is required to ensure that the dossier can be expanded as the product range is expanded or reduced by the submission of later sequences. Please see [Annex 3](#) for further details.

### 3.2 Module 1 eCTD Envelope, Administrative Information and Prescribing Information Folder

#### 3.2.1 General Considerations

In the case of country specific files or folders the country code should appear in the file and folder name as the differentiating marking.

“Not Applicable” Module 1 documents should not be included in the eCTD. However, when a justification for the absence of a certain document in Module 1 is required, such justification should be provided in its corresponding section in the eCTD structure. In any case, all section titles should always appear in the Module 1 eCTD backbone, displayed by the style sheet, even if these sections are not populated.

#### 3.2.2 Creation and Management of Envelope Information

The eCTD envelope should be used to describe the eCTD sequence:

<b>Country</b>	In the centralised procedure, there should only be one envelope, and this should have the entry ‘ema’. For MRP/DCP, each country in the procedure needs to have a separate envelope entry. ‘Common’ must not be used as a country identifier in the envelope. In case of submissions to EDQM the envelope needs to display the entry ‘edqm’.
<b>Identifier</b>	A UUID as specified by ISO/IEC 11578:1996 and ITU-T Rec X.667   ISO/IEC 9834-8:2005. The same UUID will be used for all sequences of an eCTD application.
<b>Submission Type</b>	This value represents the regulatory activity which will be started and the type of material sent to the agency. The entry is chosen from a picklist based on the <a href="#">EMA SPOR RMS</a> on Applicant Submission Type, see <a href="#">EU M1 Specification</a> for further details.
<b>Submission Unit</b>	Submission unit type describes the content at a lower level (a “sub-activity”) which is submitted in relation to a defined regulatory activity. The entry is chosen from a pick list, see <a href="#">EU M1 Specification</a> for further details.
<b>Submission Mode</b>	This element should only contain a value in variation, PSUSA or line extension regulatory activities and must be included in every sequence of that activity. The value can be set to ‘single’, ‘grouping’ or ‘worksharing’.
<b>Submission Number</b>	This number represents the high-level procedure number related to the regulatory activity in case of worksharing submissions and for submissions of grouped Type IA variations and PSUSA if <b>multiple</b> products are concerned. Samples are provided in the <a href="#">EU M1 Specification</a> . Note: not required in case only one product is concerned. If submission mode is set to either 'grouping' or 'worksharing' there should be a Submission Number (Number element in the DTD). This Number element should be identical with the variation procedure number included in a Variation eAF.
<b>Procedure tracking number</b>	Always to be completed. In case of using the submission number, the Procedure Tracking Number (PTN) refers to the product involved in the worksharing, grouped

or PSUSA procedure. Any value used by an agency or applicant to track the submission, in any procedure, in relation to a particular product, e.g. EMEA/H/C/000123 for a CP submission (after allocation of the specified procedure number by EMA) and DE/H/0126/001/MR for an MRP submission (depending from the national business rules which might allocate procedure tracking numbers at receiving time point only. In those cases the field remains empty until submission). If the PTN is not known in advance, it is recommended to use the product number instead. For a full list of expected number types per agency refer to EU M1 Specification. Note: When a submission is not relevant for all products covered by the dossier or new products are added to the dossier, please clearly state this in the cover letter.

This number should be congruent with the variation procedure number included in a Variation eAF or with the procedure number included in a MAA eAF or in a Renewal eAF.

#### **Applicant**

Entries for 'applicant' should be consistent for all eCTDs from any single applicant (legal entity), as they define where eCTDs are stored in internal systems. Consistency of spelling is also relevant over time to allocate the eCTD correctly. In case of 'worksharing' procedures, only the name of the applicant designated for the worksharing submission should be used.

#### **Agency Code**

Select from picklist in the most recent EU M1 Specification. Ensure that Country and Agency name is consistent.

#### **Procedure type Invented-name**

The entry is chosen from a picklist, see [EU M1 Specification](#) for further details.

The trade name/invented name for the medicinal product covered by the application. If the eCTD covers multiple strengths or dosage forms, this entry does not need to describe the complete name, a simple entry, for example, 'Wonderdrug' will suffice.

#### **INN Sequence**

The International non-Proprietary name for the drug substance.

The sequence number here must match the sequence number in the folder structure, on the Cover letter and on the XML delivery file for CESP submissions, the file naming conventions for eSubmission Gateway/Web Client submissions and the XML delivery file for PSUR submissions via the eSubmission Gateway/Web Client. If the submission is provided on CD/DVD this should match the label of the CD/DVD.

#### **Related-sequence**

For a description and example of how to use the 'related sequence' entry, see [Section 2.9.4](#) and the [EU M1 Specification](#).

#### **Submission-description**

This element is used to describe this particular eCTD sequence.

### **3.2.3 Module 1.0 Containing Cover Letter and Tracking Table**

#### **3.2.3.1 Cover Letter**

The cover letter should always be submitted with the document operation attribute "new". As eCTD viewing tools will display all "new" leaf elements in a current or cumulative view, it is recommended that additional descriptive text is included in the leaf title to help identify specific cover letters. This will help identify each cover letter leaf and the submission it is in, rather than having the cover letters named the same in each sequence. Some examples for the leaf titles could be:

Cover Letter for Sequence 0000

Cover Letter for Germany for Sequence 0000

Cover Letter for France for Type II Variation 028 (0042)

Please see also the [CMDh website](#) for requirements of signed paper copies of the cover letter and application form to each NCA. Please note, when resubmitting content due to technical validation issues or sequences missing at NCA side, a note (a comment in the delivery file (CESP, working documents or separate note in case of CD/DVD submissions) may be provided to clarify the reason for resubmitting and the original cover letter in the eCTD should not be changed, see [Section 2.9.4](#). For submissions to the EMA it is mandatory to use the eSubmission Gateway / Web Client and no additional comment is required.

For MRP / DCP guidance a cover letter template is provided at the [CMDh webpage](#).



### 3.2.3.2 Tracking Table

A tracking table should always be included as an annex to the cover letter for submissions within all procedures. The file should be named *cc-tracking-var.pdf* and be placed in /XXXX/m1/eu/10-cover/cc (e.g. ema-tracking-var.pdf for a CP, common-tracking-var.pdf in an MRP/DCP, or be-tracking-var.pdf in a NP.)

Examples of Tracking tables to be used within the MRP/DCP are found in the CMDh guidance '[CMDh Best Practice Guide on the use of eCTD in the MRP/DCP](#)'. An example of a Tracking table that would be suitable for a centralised or a national procedure can be found in Annex 2 below.

### 3.2.4 Application Forms

The application form should always be submitted with the document operation attribute "new" (as for the cover letter, see above), unless an error has been made in the form and an updated application form is being provided in a new sequence, in which case the operation attribute should be "replace".

Some NCAs do require the application form to be submitted as a signed paper original together with the eCTD submission. Please refer to the [CMDh website](#) for submission requirements or the individual NCA's web sites for further details.

The file named cc-form-eaf.pdf (without using any variable part of the file name) should be used if only one eAF is provided. However, if more than one eAF is included in the m1.2, they should be differentiated by the use of the variable part (e.g. cc-form-eaf-10mg and cc-form-eaf-20mg).

Supportive documents, which are not part of any M2-5 section or Response to Questions, should be placed in the application form section 1.2. of the eCTD as separate files, and not appended to the form itself. Each annex to the eAF should be provided as a separate attachment in m1/eu/12-form/cc, using the variable part of the file name and the leaf title to clearly describe the content of the document. E.g. file name: fr-form-annex-proofpayment.pdf, Leaf Title: "France, Proof of Payment".

### 3.2.5 Product information

Product information should be supplied as PDF files within the eCTD. In addition, MS Word files (with or without tracked changes as relevant) should be provided in the separate folder XXXX-workingdocuments (see section 2.9.10) within the same submission. Alternatively, certain procedures require word working files to be sent via Eudralink. Details can be found in [Section 2.9.9](#) and from [Section 4. Advice on specific application types](#).

In MRP/DCP national translations should be managed outside of the eCTD (see CMDh guidance '[CMDh Best Practice Guide on the use of eCTD in the MRP/DCP](#)').

In MRP/DCP, ensure that common product information is always placed under m1/eu/13-pi/131-spclabel/common/en. If these documents are placed under country specific folders, e.g. the country folder of the RMS, the agencies will not be able to use the country filtering options of their eCTD viewer tools as intended.

In the Centralised Procedure, national translations are only required in the eCTD for the commission decision documents in a closing sequence. However, for variations Type IA, the national translations should always be provided with the first submission, if relevant. Please refer to [Section 4.1](#). More information on requirements for Centralised Procedure post-authorisation procedures can be found from [here](#).

### 3.2.6 Use of Response Documents Section

The submission of electronic information in response to a list of questions from NCAs and EMA should follow the same basic principles as the first submission. The written response should be submitted following the EU recommended response folder and file structure. Please ensure that all documents are aligned with the CTD structure (refer to [Notice to Applicants Volume 2B](#)), using the operation attributes of "new", "replace", or "delete" as appropriate. ("Append" should be avoided, see [Section 2.9.6](#).)

To help in the management of responses over the lifecycle of the eCTD, the responses relating to a particular regulatory activity should be grouped under a node-extension in the eu-regional.xml file. The title of the node-extension should identify the regulatory activity (e.g. Responses to Questions for the Initial Application, Responses to Questions for Type II Variation 028, etc.). It is recommended that the applicant provides a full copy of the list of questions received from the agencies as the first leaf in this section.

It is recommended that the responses be split up into separate files for each major section of the submission (e.g. Quality, Non-clinical and Clinical). Leaf titles should be used to identify the particular set of responses (e.g. Response to Major Objections - Quality). If responses to more than one question are submitted in a single file bookmarks should be used within the PDF file to clearly identify each response. It is possible to submit the response to each question in a separate file but in that case node-extensions must be used and leaf titles to group and identify the responses under the top-level node-extension.

In MRP/DCP, all files for the response documents should be placed in the folder m1/eu/responses/common, regardless which member state raised the question.

In m1-responses/cc, it is recommended to use the variable component of the filename and the leaf title, to present the information clearly to the assessor. The response files should preferably be named as:

*cc-responses-<regulatory activity type identifier>-<timeline identifier>-<content identifier>.pdf*, using the -var component of the filename to define the content.

**Table 7 : Examples of Filenames and Leaf Titles for Response Documents**

<b>Suggested Filename</b>	<b>Suggested Leaf Title</b>
common-responses- <i>maa-d106-clin</i> .pdf	Day 106 Clinical Responses, MAA
common-responses- <i>maa-d120-clin</i> .pdf	Day 120 Clinical Responses, MAA
common-responses- <i>maa-d145-clin</i> .pdf	Day 145 Clinical Responses, MAA
common-responses- <i>maa-d120-clinq4</i> .pdf	Day 120, Clinical Response Question 4, MAA
common-responses- <i>maa-d120-clinq7</i> .pdf	Day 120, Clinical Response Question 7, MAA
common-responses- <i>var03-d45-clin</i> .pdf	Day 45 Clinical Responses, Var03
common-responses- <i>var03-d59-clin</i> .pdf	Day 59 Clinical Responses, Var03
common-responses- <i>maa-d106-qual</i> .pdf	Day 106 Quality Responses, MAA
common-responses- <i>maa-d120-qual</i> .pdf	Day 120 Quality Responses, MAA
common-responses- <i>maa-d145-qual</i> .pdf	Day 145 Quality Responses, MAA
common-responses- <i>var05-d44-qual</i> .pdf	Day 44 Quality Responses, Var 05
common-responses- <i>var05-d59-qual</i> .pdf	Day 59 Quality Responses, Var 05
common-responses- <i>var12-d33-qual</i> .pdf	Day 33 Quality Responses, Var 12

### 3.2.7 Use of the Additional Data Section

The section 'Additional Data' should only be used for nationally required information in National, Mutual Recognition and Decentralised Procedures. An exemption to this is the use of this section for justifications for active substances or justification of eligibility of the product for the Centralised Procedure.

In addition, this section can be used for all procedures when an old version of a DTD is being used during an agreed transition period, to support inclusion of a newly defined section of Notice to Applicants (refer to transition guidance issued with specification updates).

## 3.3 Module 2 Overviews and Summaries Folder

### 3.3.1 General Considerations

Each document should be provided as an individual PDF.

### 3.3.2 Structure of Module 2 Documents

In module 2.3 Quality Overall Summary (QOS) either one file (qos-var.pdf) or separate files per QOS section can be submitted named as: introduction-var.pdf, drug-substance-var.pdf, drug-product-var.pdf, appendices-var.pdf and regional-information-var.pdf. For details refer to the 'File-Folder Structure & Names' tab in the EU Validation criteria spread sheet.

Where the application includes an active substance covered by an Active Substance Master File (ASMF), the Applicant should submit the QOS on the applicant's part of the ASMF as a separate file in module 2.3 of the

MAA. If there are more than one ASMF, there should be a separate file for each QOS. The Applicant should ensure that each QOS has a front page clearly stating the version number and date.

If an existing document is revised, the lifecycle operator 'replace' should be used. However, if changes of content only affect one section of that document then updates should normally be submitted as a separate summary with the document operation attribute "new" as it would help clarifying what to assess within the specific submission.

For submissions covering multiple indications, refer to [Section 3.6.1](#).

## 3.4 Module 3 Quality Folder

### 3.4.1 Module 32S drug substance

This section will give guidance on how to structure the documentation related to the drug substance. Also, please find an example in [Annex 3](#).

In relation to the active substance manufacturer's documentation, the documentation can be part of the complete dossier, be presented as an Active Substance Master File (ASMF) or be covered by a Certificate of Suitability (CEP). The Applicant should provide the documentation on the active substance as relevant in these different situations.

For biological/biotechnological and Advanced Therapeutic Medicinal products, where the whole active substance documentation would be presented as part of the complete dossier, it is recommended that only *one* drug substance module (m32s section) should be created even if several active substance manufacturers are used. If there are several different active substances in one finished product (combination product), the documentation should be presented as one drug substance module (m32s section) per active substance.

For all chemical products and products covered by an ASMF, please see the following sections for different scenarios.

#### 3.4.1.1 Active substance documentation for chemical products and products covered by an ASMF

For the documentation on the active substance for chemical products and products covered by an ASMF, it is important to differentiate between:

- The active substance manufacturer's documentation on the active substance
- The Applicant's documentation on the control of the active substance

The active substance manufacturer's documentation covers how the active substance is manufactured and controlled by the active substance manufacturer to ensure the quality of the active substance (see 3.4.1.1.1).

The Applicant's documentation covers how the active substance is controlled by the finished product manufacturer(s) to ensure the quality of the active substance (see 3.4.1.1.2). This would only be applicable when the active substance and the finished product are manufactured at different sites.

Both the active substance manufacturer's documentation and the Applicant's documentation on the active substance should be provided in the eCTD dossier, as relevant.

Where the application includes an active substance covered by an Active Substance Master File (ASMF), the Applicant should submit the applicant's part of the ASMF in module 3.2.S. The Applicant should ensure that the front page of the applicant's part, clearly stating the version number and date, is also included in the product eCTD dossier either as the first page of the first document (i.e. in the nomenclature document) or as a separate file placed in Module 3,2.S.1.1, called *nomenclature-cover page applicant's part.pdf*.

##### 3.4.1.1.1 Active substance manufacturer's documentation on the active substance

The documentation can be part of the complete dossier, be presented as an Active Substance Master File (ASMF) or be covered by a Certificate of Suitability (CEP). The Applicant should accordingly provide the complete documentation on the active substance, the applicant's part of the ASMF or the CEP, as relevant.

**a) If more than one active substance manufacturer for the same active substance**

When the active substance manufacturer's documentation is presented as an Active Substance Master File (ASMF), one drug substance module (m32s section) should be created per ASMF i.e. each applicant's part should be presented in its own drug substance module.

When the active substance manufacturer's documentation is part of the complete dossier (i.e. not provided as an ASMF), one drug substance module (m32s section) can be created per active substance manufacturer or one drug substance module (m32s section) can be created covering all active substance manufacturers, depending on whether the documentation is largely similar or not (and same route of synthesis applies).

When the active substance is covered by a CEP, each CEP should be placed in module 3.2. Regional Information (and in Module 1.2 as annex 5.10). If needed, a separate m32s should be created for each active substance manufacturer, where relevant sections of 3.2.S.1 to 3.2.S.7 folders should be used for any additional documents (e.g., for information not covered by the CEP).

**b) If multiple active substances in one finished product**

Where there are multiple active substances in one finished product (combination product), one drug substance module (m32s section) should be created per active substance and the above guidance for several active substance manufacturers should be followed.

**3.4.1.1.2. Applicant's documentation on control of the active substance**

The Applicant is responsible for ensuring the quality of the active substance. The applicant should therefore have their own drug substance module (m32s) covering the control of the active substance performed by the finished product manufacturer(s) when the active substance and the finished product are manufactured at different sites.

**a) If more than one active substance manufacturer for the same active substance**

The Applicant's documentation on the active substance should be *compiled* as stated in the guideline "*Guideline on Active Substance Master File Procedure*". This requirement is the same whether the documentation on the active substance is part of the complete dossier, presented as an ASMF or is covered by a CEP.

As the Applicant's documentation on the active substance should always be compiled, there should only be *one* drug substance module (m32s) per active substance. It is *not* acceptable to submit the Applicant's documentation divided into different drug substance modules, even if there are several different active substance manufacturers. It is also *not* acceptable to provide the Applicant's documentation as separate drug substance modules even if there are several different finished product manufacturers.

**b) If multiple active substances in one finished product**

Where there are several different active substances in one finished product (combination product), the Applicant's documentation should be presented as one drug substance module (m32s section) per active substance.

If an existing eCTD is not structured in line with the above guidance, the dossier should be restructured with the next submission of a quality variation that affects the relevant content.

See also section 4.7 for information on Active Substance Master Files.

**3.4.2 Module 32p drug product**

This module can be repeated and each dosage form (for example film-coated tablets and capsules) covered by an eCTD dossier should always be described in its own *m32p* section.

If an application includes multiple strengths of one dosage form, the documentation covering all strengths is recommended to be provided in the same *m32p* section whether or not the documents are strengths specific or combined. If there are some strength specific documents, it would still be recommended to include these in

the same m.3.2.p section. However, if there are substantial differences between the manufacturing or quality control of a strength, it might be justified to have a separate module 3.2.p section. The approach should preferably be described in the cover letter.

There should only be *one m32p* section even if there are multiple finished product manufacturers. It is *not* acceptable to provide one m32p section per finished product manufacturer for the same dosage form of the finished product. The description of the manufacturing process should be provided as one document within the m32p section (in module 3.2.P.3.3). Please see "[Guideline on manufacture of the finished dosage form](#)" for further guidance. §

If an existing eCTD is not structured in line with the above guidance, the dossier should be restructured with the next submission of a quality variation that affects the relevant content.

## **3.5 Module 4 Nonclinical Study Reports Folder**

### **3.5.1 Guidance on the Handling of Granular Study Reports**

Submissions created in eCTD format for the use within the FDA may provide more granular study reports using study tagging files. There is no need to re-organise the reports for submission to the EMA or NCAs. See [Section 3.6.2.](#) below for further information.

## **3.6 Module 5 Clinical Study Reports Folder**

### **3.6.1 Management and Handling of Multiple Indications**

In cases where the application includes multiple therapeutic indications, the reports should be organized in a separate Section *m535* for each indication. In such cases, if a clinical efficacy study is relevant to only one of the indications included in the application, it should be included in the appropriate section in *m5* (e.g. *m5/53-clin-stud-rep/535-rep-effic-safety-stud/anxiety/5351-stud-rep-contr*). If a clinical efficacy study is relevant to multiple indications, the study report should be included in the most appropriate subsection of *m535* and referenced as necessary in the equivalent section under the different indication. In Module 2, a separate “Summary of Clinical Efficacy” module should be submitted for each indication, although closely related indications can be within a single document.

Regardless of which way is chosen, it is important to provide clear written guidance to the assessor when the supportive data/study report documents are applicable to more than one indication.

### **3.6.2 Management and Handling of Granular Clinical Study Reports**

ICH Q&A 22 recommends use of E3 granularity for clinical study reports. In Europe, node extensions should be used to group together individual files. If a US NDA is repurposed for submission in the EU, the study content (the study report and any relevant appendices) should be placed under a node extension. The STF xml file itself and any content not required for the EU submission (e.g. datasets) should be removed, but submissions still containing STF files will not be rejected. In order to maintain a consistent looking eCTD lifecycle and table of contents (via *index.xml*), applicants are advised to use node extensions for all clinical study reports, regardless of the granularity of the content (i.e. even reports that consist of only one document should also be presented in node extensions). See also [Section 2.9.8](#) Node-extensions.

### **3.6.3 Provision of CRFs and Data when Requested**

If case report forms and individual patient data listings are submitted in *m537* (as appendices 16.3 and 16.4 in the ICH clinical study report guideline E3) they should be placed in the same order as the clinical study reports appearing in *m535* and should be indexed by study. Please note that bookmarks will not be required as there will be no further internal structure.

### **3.6.4 Provision of Synopses of Individual Studies**

It is acceptable either to include copies of the synopses for each study in eCTD section 2.7.6 or to provide hyperlinks to synopses located in Module 5 without providing copies in section 2.7.6. In either case a Listing of Clinical Studies should be provided and this should include hyperlinks to the first page of each synopsis.

### **3.6.5 Company Core Data Sheet**

If companies submit their Company Core Data Sheet, this is recommended to be provided in eCTD section 5.3.6, Post Marketing Experience.

## 4. Advice on Specific Application Types

### 4.1 New MA Applications

The recommended start for an eCTD lifecycle is the initial MA application. It should normally be provided as sequence 0000. To start with another number should be justified in the cover letter. All documents included should have the operation attribute “new” and be placed in the relevant sections in line with the different eCTD specifications.

The submission type should be ‘maa’.

See [Section 2.9.5](#) for an example on the use of the submission units.

For responses to questions documents, see [Section 3.2.6](#).

The following milestones of the procedures are proposed as appropriate sequences to be submitted during the assessment of a new application.

**Table 8 : MAA – Centralised Procedure**

<b>Day Number/ Milestone</b>	<b>eCTD milestone sequence</b>	<b>Notes</b>
Submission deadline	Initial submission	As per published submission calendars
-5 or as requested before date of start	Response to business validation issues	If required
121	Response to List of Questions (LoQ)	If applicable
181	Response to List of Outstanding Issues (LoOI)	If applicable
Any time between D181-220	Redaction Proposal Document Package	For details see <a href="#">Section 4.12</a>
Commission Decision + 15 days or prior to the next regulatory activity whichever is first.	Decision / Closing sequence – including final translations  Updates to the dossier which have not yet been submitted in eCTD but which have been agreed by the CHMP at the time of the opinion; e.g. <ul style="list-style-type: none"> <li>• Final RMP</li> <li>• Minor updates to Module 2 or 3</li> <li>• Final Product Information (Annex I, II, IIIA, IIIB and Annex A) in all languages</li> <li>• Final mock-ups reviewed during the procedure.</li> </ul>	I.e. final amended documentation if any changes occur during the Standing Committee phase (SCP)  Except from changes during the SCP, the documentation submitted within this eCTD sequence should be identical to the documents submitted to the EMA at the time of the CHMP opinion via EudraLink.
20 calendar days post consultation notification	Final Redacted Document Package	For details see <a href="#">Section 4.12</a>

**Table 9 : Centralised Procedure - Outside eCTD via EudraLink**

211 (opinion + 1)	Final English PI	
Opinion + 5	Provision of translations	
Opinion + 25	Provision of final agreed translations following linguistic review	

**Table 10 : New MAA – Decentralised Procedure**

<b>Day Number/ Milestone</b>	<b>eCTD milestone sequence</b>	<b>Notes</b>
- 10	New MAA	
Procedure start	Validation update	If required
106	Day 106 Responses to questions	
210	Final agreed EN product information	Or at any day when the procedure can be closed after agreement is reached.

For further details on MRP and DCP, please refer to the '[CMDh Best Practice Guide on the use of eCTD in the MRP/DCP](#)'.

## 4.2 Variation Applications

All types of variations should be submitted within the eCTD as new sequences.

Documents related to the variation should be included in relevant sections or be deleted or replaced by use of the appropriate document operation attribute. Where documents cannot be assigned to specific CTD defined locations, then they should be provided as annexes to the m1.2 Application Form.

The submission type should reflect the type of variation. ([See Q&A for Variations in eCTD](#)). Submissions for workshare/grouping variations (containing MRP/DCP/National products only) concerning several eCTD submissions are recommended to be supplied together in a single zip file, refer to [section 2.12](#). The zip file should contain clearly marked subfolders for each product eCTD dossier (each specific UUID) that takes part in a worksharing or grouping procedure.

For worksharing procedures containing only CAPs or worksharing procedures containing CAPs and MRP/NAPs a separate submission for each eCTD via the eSubmission Gateway/Web Client only is required. In case of worksharing procedures containing CAPs, the submissions for nationally authorised products (MRP/DCP/NP) should be sent to EMA only via the eSubmission Gateway/Web Client. There should be no additional submissions directly to NCAs.

See [Section 2.9.5](#) for an example on the use of the submission units.

For details on how to handle parallel variations, please refer to [Annex 4](#) of this guidance.

Although Type IA variations usually should not be revised if they are invalid from regulatory point of view, it is necessary to correct technical invalid submissions in the same way as required for any other eCTD sequence.

The following milestones of the procedures are proposed as appropriate sequences to be submitted during the assessment of variations. Although the example relates to the Centralised Procedure the principal could be applied to other procedures (except for final translations).



**Table 11 : Type II Variations – Centralised Procedure**

<b>Day Number / Milestone</b>	<b>eCTD milestone sequence</b>	<b>Notes</b>
Submission deadline	Initial submission	Please observe the <a href="#">published submission timetables</a> , e.g. “Start of the procedure, new indication”
-5 or as requested before date of start	Response to business validation issues	If required
RSI Submission deadlines	Response to Request for Supplementary Information (RSI)	If applicable
Opinion + 30	For Type II variations which are <b>not</b> followed by an immediate Commission Decision:  Decision / Closing sequence – including final translations if applicable  Updates to the dossier which have not yet been submitted in eCTD but which have been agreed by the CHMP at the time of the opinion; e.g. <ul style="list-style-type: none"> <li>• Final RMP</li> <li>• Minor updates to Module 2 or 3</li> </ul> Final Product Information (Annex I, II, IIIA IIIB and Annex A) in all languages	For Type II variations which are <b>not</b> followed by an immediate Commission Decision
Commission Decision + 15 days or prior to the next regulatory activity whichever is first.	For Type II variations following worksharing or with immediate Commission Decision: Decision / Closing sequence – including final translations if applicable  Updates to the dossier which have not yet been submitted in eCTD, but which have been agreed by the CHMP at the time of the opinion, e.g. <ul style="list-style-type: none"> <li>• Final RMP</li> <li>• Minor updates to Module 2 or 3</li> <li>• Final Product Information (Annex I, II, IIIA IIIB and Annex A) in all languages</li> <li>• Final mock-ups reviewed during the procedure.</li> </ul>	For Type II variations following worksharing or with immediate Commission Decision

**Table 12 : Type IA & IB Variations – Centralised Procedure**

<b>Day Number</b>	<b>eCTD milestone sequence</b>	<b>Notes</b>
Submission	Start of the procedure <description>	e.g. “Start of the procedure, phone number changes”
RSI Submission deadlines	Response to Request for Supplementary Information (RSI)	If applicable

**Table 13 : Type IB Variations with linguistic review - Centralised Procedure**

<b>Day Number</b>	<b>eCTD milestone sequence</b>	<b>Notes</b>
-------------------	--------------------------------	--------------

Submission deadline	Start of the procedure <description>  English PI, clean (pdf) – inside the eCTD English PI, tracked changes + translations (MS Word) (Outside eCTD but within the same submission package in the working_documents folder)	e.g. “Start of the procedure, phone number changes”
Start + 5	Provision of translations (Eudralink)	
Start + 25	Provision of final agreed translations following linguistic review (Eudralink)	
RSI Submission deadlines	Response to Request for Supplementary Information (RSI)	If applicable
Notification + 15	Closing sequence – including final translations, clean (pdf) inside the eCTD	

For MRP and DCP, please refer to the CMDh guidance '[Requirements on submissions for New Applications within MRP, DCP or National procedures](#)'.

### 4.3 Extension Submissions

Several dosage forms can be managed within a single eCTD application, and this helps to avoid submission of data multiple times (e.g. active substance changes). Submissions for an extension can either be submitted within an existing eCTD application, as a new sequence (continuous sequence numbering), or as a new eCTD application (sequence 0000), if a separate lifecycle management is preferred (not applicable in the Centralised Procedure, see below).

In **MRP/DCP**, an extension will be submitted within the same procedure, but with a different product number, and as such, the recommendation is to submit the extension as a new sequence within the original eCTD application, submitting a new Module 1, an updated Module 2 and new or updated 32P section. If *m32p* is combined for all previous existing strengths/dosage form(s), an updated section should be provided, replacing existing documents where necessary. If a separate *m32p* is being provided for the additional strength/dosage form to describe the extension, then all documents should have the operation attribute of “new”.

For **extension** applications, only new data should be submitted as a new sequence in the already submitted eCTD. The submission type should be “extension”.

If single eCTDs are used for each strength or form of a product, full data concerning the extension applied for has to be included in the submitted eCTD and therefore clear information should be given to the assessor on what is new compared to earlier submitted data for the product to avoid unnecessary assessment.

In the **Centralised Procedure**, extensions are typically managed under the same procedure number as the original dosage form, and again the recommendation is to submit the extension as a new sequence within the original eCTD application, using a new *m32p* to describe the different dosage form.

For **national applications**, the applicant should discuss with the relevant NCA.

### 4.4 Renewal Submissions

Please note that a renewal application can be used as the first eCTD in a product lifecycle in a similar manner to variations. The recommendation given in the section above applies likewise.

The submission type should be “renewal”.

See [Section 2.9.5](#) on examples on the use of the submission units.

The following milestones of the procedures are proposed as appropriate sequences to be submitted during the assessment of renewals: Although the example relates to the Centralised Procedure the principal could be applied to other procedures (except for final translations).

**Table 14 : Renewals**

**5 year Renewal – Centralised Procedure**

<i>Day Number</i>	<i>eCTD milestone sequence</i>	<b>Notes</b>
Submission deadline	Initial submission	As per published submission calendar
91	Response to Request for Supplementary Information (RSI)	If applicable
Commission Decision + 15	Decision / Closing sequence – including final translations if applicable  Updates to the dossier which have not yet been submitted in eCTD but which have been agreed by the CHMP at the time of the opinion; e.g. <ul style="list-style-type: none"> <li>• Final RMP</li> <li>• Minor updates to Module 2 or 3</li> <li>• Final Product Information (Annex I, II, IIIA, IIIB and Annex A) in all languages</li> </ul>	

**Annual Renewal of conditional marketing authorisation – Centralised Procedure**

<i>Day Number</i>	<i>eCTD milestone sequence</i>	<b>Notes</b>
Submission deadline	Initial submission	As per published submission calendar

**Table 15 : Centralised Procedure – Outside eCTD via EudraLink**

Opinion + 1	Final English PI	
Opinion + 5	Provision of translations	
Opinion + 25	Provision of final agreed translations following linguistic review	

For renewals in MRP and DCP, the general principles in the CMDh guidance [‘CMDh Best Practice Guide on the use of eCTD in the MRP/DCP’](#) can be applied.

## 4.5 PSURs

As per the Article 107b paragraph 1 and Article 28(2) Regulation 726/2004) all Periodic Safety Update Reports (PSUR) shall be submitted electronically. The use of the PSUR Repository is mandatory for all human products authorised in the EU (CP, MRP, DCP and NP). The use of the PSUR Repository is mandatory for all products regardless if the product is included in an EU PSUR Single Assessment Procedure or if the assessment is part of a national procedure. The submission to the PSUR Repository is always required and it is important to indicate the PSUSA procedure number for all submissions included in a PSUSA procedure.

As per the HMA eSubmission Roadmap the use of eCTD format is now mandatory for all procedure types within EU, including purely nationally authorised products. Since the PSUR is a part of the product lifecycle it should be provided as the next relevant sequence in the products eCTD lifecycle. This applies to all products within all authorisation procedure (CP, MRP, DCP and NP), also for those for which the PSUR is part of an

EU PSUR Worksharing procedure for NAPs or the EU PSUR Single Assessment (PSUSA) procedure for CAPs and NAPs.

A separate PSUR eCTD sequence must be submitted for each respective eCTD lifecycle, even if the PSUR document covers multiple products.

If a single PSUR has been prepared covering multiple products a separate submission (of that same PSUR document) must be made for each respective product.

However, to facilitate the assessment, it should be clarified in the cover letter that the submitted documentation in each separate eCTD sequence is identical in relevant parts. For PSUR submissions under PSUSA procedures, the grouped submission feature in the PSUR repository should be used. Separate standalone eCTD sequences grouping multiple products must not be created.

The submission of a PSUR should be included in the eCTD as a new document in *m536* as well as a new or replace document in *m25* as necessary. Any literature should be included in *m533* or *m54* as appropriate. The naming of the leaf element in *m536* shall indicate the number of the PSUR or the period covered.

According to the guidance set out in [GVP module VII on PSURs](#), proposed changes to the EU labels as a result of the PSUR data should be provided under Section VII.C.5.1. PSUR EU regional appendix, sub-section "Proposed [product information](#)" of the PSUR.

For CAPs, the proposed product information should also be submitted to Module 1.3.1 of the eCTD.

It should be presented as a tracked change version of each EU SmPCs and package leaflet of the products concerned and each [product information](#) should be translated into English language including the tracked changes proposed, in order to enable the EU single assessment.

This can result in having to submit a large number of sets of tracked change product information with the additional burden of providing translations. Hence MAHs can consider the option to focus on the proposed amendments to SmPC and package leaflet. In such case, only the amended parts of the SmPC and package leaflet should be provided in track changes and in English language under the EU regional appendix. Where the proposed changes are not based on the data submitted within the PSUR, these will not be considered, and a variation will have to be submitted as appropriate to the relevant national competent authority.

In case no changes to the product information are being proposed as part of the PSUR, the MAH should not include any product information within the EU regional appendix.

Amendments to the SmPC, package leaflet and labelling, as a result of the PSUR assessment, should be implemented without subsequent variation submission for CAPs and through the appropriate variation for NAPs, including those authorised through MRP or DCP.

When multiple products from the same MAH are covered by the PSUR, all products must be listed in the cover letter.

The submission type should be "psur" for 'pure, single PSURs', i.e. those products for which the active substance is not included in the EURD list.

For PSURs included in the EU PSUR Single Assessment (PSUSA), the submission type is "psusa"

See [Section 2.9.5](#) for an example on the use of submission unit.

More information on the submission of PSUR submissions can be found from the [EMA Post-Authorisation Guidance](#). Please also refer to the [PSUR Repository website for the most recent information](#).

**Note:** MAHs should not submit full study reports as part of a PSUR. Final study reports should always be submitted as a C.1.13 variation. In the case of interim PASS study results, these can be summarized in the PSUR under the section "*Findings from non-interventional studies*" or alternatively if the reporting to EMA does not coincide with the PSUR submission, the full interim report should be submitted as a separate, stand-alone submission (post-authorisation measure (PAM)) relevant to CAPs only.

Additionally, submission of RMP updates cannot be accepted with PSURs subject to a PSUSA of:

- a mixture of CAPs pertaining to different GMAs;
- a mixture of centrally and nationally authorised medicinal products;
- a mixture of NAPs.

The submission of an imposed, non-interventional Post Authorisation Study protocol or study report should not be combined with a PSUR or PSUSA sequence. Please, use the submission type 'pass107n' in case of the protocol and 'pass107q' in case of the study report.

For follow-up (MAA-LEG) procedures within the Centralised Procedure, please refer to the [EMA Q&A on post-authorisation measures](#).

Regarding PSUFU submission, i.e. follow-up submissions for NAPs, please see technical details in the [CMDh guidance for PSUFU](#).

## 4.6 Referrals

The eCTD format is mandatory for all referral submissions. There are, however, some difference in the handling depending on the type of referral, as described below. Regardless these different handlings during the referral procedure, any variation application required after a referral outcome should always be submitted in eCTD format per concerned product eCTD dossier.

### 4.6.1 CMDh referrals related to MRP/DCP/RUP

CMDh referrals would be product specific as a result of different positions within a MRP/DCP procedure and should be included in the product eCTD as a next sequence in the lifecycle. The response from the applicant to the referral list of questions should be sent as an eCTD sequence to all CMD(h) members, according the timelines as defined, even if all NCAs would not have the starting sequences for that product (i.e. are not involved in the MRP/DCP procedure).

The type of submission of this sequence should be "referral" with the relevant submission unit (see section 2.9.5).

### 4.6.2 EMA-led referral procedures

Referral submissions concerning CAPs only and all EMA-led referrals where also National products are included (NP, MRP, DCP products) should be sent via EMA eSubmission Gateway or eSubmission Web Client only. They are available via the Common Repository and considered delivered to all National Competent Authorities (NCAs) and scientific group experts. No additional copies of the submissions should be sent directly to the NCAs as this might lead to validation issues and cause delays.

For CAPs, referral submissions should always be submitted as the next sequence in the product lifecycle for each CAP. Standalone eCTD submissions for the referral (on active substance basis) are not allowed for any CAPs included in referral procedures. However, for EMA led referral procedures where only MRP, DCP and NP products are included, a stand-alone eCTD lifecycle is recommended to cover all the concerned nationally authorised products.

New documentation/information/responses should be included as a new eCTD sequence. The type of submission of the new sequence should be "referral" with the relevant submission unit (see section 2.9.5).

In case of a newly created/submitted sequence, the cover letter contains background information for the reason of the referral. Any other document, which concerns the referral, should be included according to the eCTD structure. Any additional documentation that does not have a relevant placeholder in the dossier, for example an overview of the registrations/applications involved in the referral, should be placed in m10-cover.

Please refer to [Dossier requirements for referral procedures](#) for more details.

## 4.7 Active Substance Master Files

For Marketing Authorisation Applications (MAAs) in eCTD format, where the documentation on the active substance is presented as an Active Substance Master file (ASMF), the applicant should incorporate the applicant's part (AP) documents of the ASMF and the Quality Overall Summary (QOS) on the applicant's part of the ASMF into the eCTD structure as per the relevant guidelines. It is recommended to use a suffix of '-ap' on the filename of these documents.

The ASMF Holder should provide the full ASMF, i.e. both the Applicant's and the Restricted part in eCTD format to the relevant authorities. The Applicant's part and the Restricted part should each have a front page clearly stating the version number and date.

The ASMF should include a QOS on the Applicant's part and a separate QOS on the Restricted part. Each QOS should have a front page clearly stating the version number and date.

For further information, please refer to the *EU Harmonised Technical Guidance for ASMF Submissions in eCTD format* at the [eASMF page](#) on the [eSubmission website](#).

A copy of the "Letter of Access" addressed to the relevant regulatory authority included as Annex 5.10 of the application form should be placed in m12/cc (i.e. in the respective folder for each concerned authority).

## **4.8 Vaccine Antigen Master Files**

The VAMF consists of the scientific data according to Part III of Annex I of [Commission Directive 2001/83/EC](#) as amended. To support the lifecycle, keep the documents manageable and to assure the correct alignment of the complete VAMF it is required that the manufacturer submits the VAMF (including versioning), preferably in an electronic format following the principles of eCTD. The complete VAMF can be processed with its own submission / case / procedure number separately.

The application of a medicinal product will contain the same data package including the certificate of compliance with Community legislation, together with the evaluation report attached.

## **4.9 Plasma Master Files (PMFs) and medicinal products containing PMFs**

### **4.9.1 Plasma Master Files**

The Plasma Master File documentation for certification is submitted to the EMA as a stand-alone eCTD dossier of a medicinal product. This documentation contains all the information related to the starting material for the manufacture of the medicinal product but submitted separately from MAA dossier (EC Regulation Commission Decision 2003/83/EC, part III of Annex I) when follows the PMF certification evaluation procedure.

ePMF should be provided within the 'workingdocuments' folder for PMF certification submissions.

For practical on PMF eCTD guidance, the reader is referred to see the PMF eCTD Guidance document found via this [link](#). More information on PMF submission can be found [here](#).

### **4.9.2 Medicinal products containing PMFs**

All concerned medicinal products that include one or more plasma supplier in their dossier (i.e. one or more PMF(s)) are required to have their dossier updated and implement any updates by submitting the relevant variations to the MA (see point 4.2 above).

## **4.10 Applicant Initiated Withdrawals of the MA or certain strengths or dosage forms**

Applicants may decide to withdraw their marketing authorisation during any stage of the product lifecycle and this section explains the general principles that should be followed in terms of managing the eCTD lifecycle.

If the application for withdrawal does not include all strengths and/or dosage forms covered by the same eCTD, the application should be submitted as a new sequence, with the operation attribute "delete" for documents that are no longer relevant. Furthermore, if relevant, it should also include updated documents with the operation attribute "replace" for documents that covered several other strengths and/or dosage forms and that now need to be revised to exclude the withdrawn strengths and/or dosage forms from the document.

Withdrawal of the whole product (all dosage forms and strengths) covered by an eCTD should preferably be submitted as a new sequence only including a cover letter with the request of withdrawal. The operation attribute “delete” is not required to be used for the documents.

The submission type ‘withdrawal’ or the relevant variation category for the change, depending on the regulatory procedure being followed should be used.

## 4.11 Applicant Withdrawal or Agency Rejections of Post-Authorisation Regulatory Activities

If a regulatory activity is withdrawn, fully or partially or rejected fully or partially, then the documentation has to be updated accordingly with a **consolidation** sequence. Documents that are no longer relevant should be deleted, and documents where the content needs to be adjusted to reflect the withdrawal or rejection be replaced. The application form and cover letter should always be retained to keep the history. A consolidation sequence should be submitted to restore the current view of the dossier to what it was before the rejected activity was submitted. This would also apply where documentation needs to be adjusted as a result of a commitment or a partially rejected variation. The submission type should be ‘consolidating’.

Note, it is not possible to delete a sequence from the life cycle to accommodate the withdrawal or rejection.

### Scenario on consolidation sequence

Applicant X has submitted sequences:

0027 Variation 011

0028 Day xx response

Letter of rejection of variation 011

\*\*0029 consolidating sequence to restore the previous status of dossier

0030 Variation 012

0031 = Next submission

The variation 011 has been rejected and those parts affected by the proposed variation need to be restored to present the previous status in the current view of the eCTD.

### Examples for this scenario:

\*\* After full or partial rejection of sequence 0027, (variation 011), a following sequence 0031 may change the same technical content. If the change previously applied for in variation 011 has not been fully restored, the new variation may not be displayed correctly, for example, the next submission cannot refer to content which was proposed in variation 011 but subsequently removed. Therefore, the consolidating sequence, 0029, must remove any new and now rejected content from the rejected variation, and also reinstate any documents that were deleted or replaced in sequence 0027/0028, such that sequence 0030 can itself replace or delete the content as required. i.e. Sequence 0029 must restore the current view, (in terms of what is current, not deleted or replaced), to what it was before sequences 0027 and 0028 were submitted.

## 4.12 Publication of Clinical Data for Medicinal Products

Clinical reports will be published, under Policy 0070 (The European Medicines Agency [policy on the publication of clinical data for medicinal products for human use](#)) following conclusion of the regulatory decision-making in the frame of centralised marketing authorisation procedures.

Key components of the process from the point of submission by an applicant/MAH to the point of publication are following:

“Redaction Proposal Document” package (eCTD sequence to be included in the eCTD lifecycle with the attribute « new »)

“Final Redacted Document” package (eCTD sequence to be included in the eCTD lifecycle with the attribute « new »)

For further details please refer to the [Guidance for the publication of clinical data](#):

## 4.13 Duplicate Applications

One eCTD per so called duplicate application has to be submitted and maintained separately in the post-authorisation lifecycle phase (with the possibility of including several strengths, dosage forms etc. if relevant). It should however be clearly written in the cover letter that it is exactly the same content (with the only exemption of different tradename and maybe different MAH), so that redundant review work is avoided.

Duplicates are independent marketing authorisations and therefore the eCTD lifecycle will need its own UUID. The term is used for practical reasons and understood as a MA application which is a 'copy' of another application. Duplicates can be submitted under the same legal basis as the initial application (e.g. Art. 8(3) of Dir 2001/83/EC). The legal basis of the dossier will trigger the dossier requirements. There is no definition of a "duplicate" in the pharmaceutical legislation. However, for practical purposes, a duplicate application is defined for MRP/DCP by reference to the first application or marketing authorisation as follows based on [CMD\(h\) recommendations on multiple/ duplicate applications](#):

- same dossier (copy of modules 1, 2, 3, 4 and 5);
- same legal basis according to Directive 2001/83/EC, as amended;
- different trade name;
- same or different applicant/marketing authorisation holder.

For CP specific requirements on multiple applications see the document '[Handling of Duplicate Marketing Authorisation Applications of Pharmaceutical products](#)'.

Duplicate applications should always be submitted as independent stand-alone eCTD dossiers with their own life cycles and is following eCTD life cycle maintenance rules.

## 4.14 Informed Consent Applications

An Informed consent application is an application according to Article 10c of Directive 2001/83/EC as amended. The marketing holder for the reference product has consented that the applicant could refer to all three modules containing the pharmaceutical, preclinical and clinical data for the reference product. It is not possible to use Article 10c for an application with the applicants own data for module 3 and for which consent has been given only for module 4 and 5. In case other modules than module 1 are submitted according to the requirements of the relevant national competent authorities, these other modules have to be identical with the reference product dossier.

Based on 'CMDh INFORMED CONSENT APPLICATIONS IN MUTUAL RECOGNITION AND DECENTRALISED PROCEDURES RECOMMENDATIONS':

- module 1 should always be submitted by the applicant including a letter of consent to module 3-5 as applicable.
- module 2- 5, if provided due to national requirements, must be identical with the reference product dossier.
- is not legally obliged to cover all pharmaceutical form(s)/strength(s) of the reference medicinal product,
- must have different trade name,
- same or different applicant/marketing authorisation holder,
- if an Active Substance Master File has been used for the reference product a new letter of access should be included in the application for the second product.

Within the centralised procedure, only module 1 should be submitted by the applicant including a letter of consent to module 3-5, as applicable.



# Annex 1: eCTD Reference Documents

It is recommended to regularly follow the information on the following websites:

The EMA [eSubmission website](#), with for example [the EU Module1 Specification](#) and other [eCTD v.3.2.2 EU specific information](#) like guidance documents and the EU Validation Criteria.

ICH Electronic Standards (e.g. eCTD 3.2): <https://www.ich.org/page/electronic-standards-estri>

EC Legal framework: [http://ec.europa.eu/health/documents/eudralex/index\\_en.htm](http://ec.europa.eu/health/documents/eudralex/index_en.htm)

CMDh eSubmission website: <http://www.hma.eu/277.html>

There are also other relevant information to be considered:

- [http://estri.ich.org/eCTD/eCTD\\_Specification\\_v3\\_2\\_2.pdf](http://estri.ich.org/eCTD/eCTD_Specification_v3_2_2.pdf)
- [https://admin.ich.org/sites/default/files/inline-files/eCTDQAV1\\_31\\_xlsx.zip](https://admin.ich.org/sites/default/files/inline-files/eCTDQAV1_31_xlsx.zip)
- [https://admin.ich.org/sites/default/files/inline-files/Specification\\_for\\_Submission\\_Formats\\_for\\_eCTD\\_v1\\_3.pdf](https://admin.ich.org/sites/default/files/inline-files/Specification_for_Submission_Formats_for_eCTD_v1_3.pdf)

EMA Pre authorisation guidance Q&As

- [Pre-authorisation guidance | European Medicines Agency \(europa.eu\)](#)

EMA Post-authorisation Q&As

- [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general\\_content\\_000166.jsp&mid=WC0b01ac0580023399](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000166.jsp&mid=WC0b01ac0580023399)

ICH M4, CTD information

- [ICH Official web site: ICH](#)

EU CTD information including Q&As:

- [EudraLex - Volume 2 - Pharmaceutical legislation on notice to applicants and regulatory guidelines for medicinal products for human use | Public Health \(europa.eu\)](#)

EMA Gateway:

- <http://esubmission.ema.europa.eu/esubmission.html>

Common European Submission Platform (CESP)

- <http://cesportal.hma.eu>

Electronic Application Form (eAF)

- <http://esubmission.ema.europa.eu/eaf/index.html>

EMA Quality guidelines

- [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-manufacture-finished-dosage-form-revision-1\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-manufacture-finished-dosage-form-revision-1_en.pdf)
- [https://www.ema.europa.eu/en/documents/report/final-guideline-active-substance-master-file-procedure-revision-4\\_en.pdf](https://www.ema.europa.eu/en/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf)

## Annex 2: Tracking Table Example

### A2-1 Introduction

A Tracking table is required for all eCTD submissions within all procedure types. This is an example of a Tracking table in a suitable format for submissions within the centralised or national procedures. For submissions within DCP/MRP, please refer to the CMDh guidance '[Requirements on submissions for New Applications within MRP, DCP or National procedures](#)'.

### A2-2 Tracking table example for CP and NP

#### Product Name/Number

Sequence Number	Submission Description	Submission Date
0052	Change of ANX II PAM due date (31 Oct14 to 28Feb15) - RSI (EU RMP)	Aug-2021
0051	Change of ANX II PAM due date (31 Oct14 to 28Feb15)	Jul-2021
0050	7th Annual Re-Assessment	Jul-2021
0049	CMC Store below 25C (Grouped Variation II, 2x1B)	Jul-2021
0048	Change of ANX II PAM due date (31 Oct14 to 31Jan15)	Jun-2021
0047	Contain closure system change	Jan-2021
0046	Article 61(3) (disposal warning) - Annex IIIA Labelling	Jul-2020
0045	6th - Annual Reassessment	Jul-2020
0044	Article 61(3) (disposal warning)	Jun-2020
0043	Type IAIN (Black triangle)	Jun-2020
0042	PV Supergrouping	Mar-2020
0041	MAH Address change - supergrouping	Mar-2020
0040	PV Supergrouping	Feb-2020
0039	Paediatric Article 46 application for Japanese study PGA123456	Jan-2020
0038	Commission decision	Aug-2019
0037	5th Annual Re-assessment (validation)	Jul-2019
0036	5th - Annual Re-assessment	Jul-2019
0035	Product change in retest period to 60 months	Mar-2019
0034	Type IA Super Grouped Variation to Update DDPS EMEA/H/xxxx/IG	Feb-2019
0033	5 year renewal applictaion updated during validation	Jan-2019

0032	5-year renewal for Product (EMA/H/C/xxx)	Jan-2019
0031	Periodic Safety Update Report # 7 (EMA/H/C/xxx)	Dec-2018
0030	Type II Variation to add xxx as a new adverse event (incl. validation comments)	Dec-2018
0029	Type II Variation to add xxx to the prescribing information	Nov-2018
0028	Fourth Annual Re-Assessment	Jul-2018
0027	Fourth Annual Re-Assessment	Jul-2018
0026	Response to CHMP request upon review of PSUR 6	Jun-2018
0025	Grouped Variation - Change in the specification for Immobilised PNP and Immobilised URDP	Apr-2018
0024	Grouped Variation - Registration of xxxxx as a site of manufacture	Apr-2018
0023	6th PSUR (PSU-010) for product [Period between 28-Oct-2009 to 27-Oct-2010)	Dec-2017
0022	Type IA Grouping	Nov-2017
0021	Annual Reassessment Report	Aug-2017
0020	Annual Reassessment Report	Jul-2017
0019	Annual Reassessment Report	Jul-2017
0018	Specific obligation: clarification on protocol patient inclusion criteria (PMS Study PGA111081)	Apr-2017
0017	9th PSUR for product	Dec-2016
0016	Type II Variation to update the DDPS (EMA/H/C/xxx) - Updated during validation	Dec-2016
0015	Type II Variation to update the DDPS (EMA/H/C/xxx) - Updated during validation	Oct-2016
0014	Type II Variation (Updated DDPS)	Oct-2016
0013	CMC VAR IB product - change in the retest period	Sep-2016
0012	Second Annual Reassessment and 4th PSUR for product	Jun-2016
0011	PSUR	Dec-2015
0010	Type II Variation (Updated DDPS)	Dec-2015
0009	Type IB Notification	Jul-2015
0008	Annual Reassessment	Jun-2015
0007	PSUR	Dec-2014
0006	Response to Specific Obligations	Sep-2014
0005	Pre-Opinion documentation - Letter of Commitment - Responses	Jun-2014
0004	Consolidated Responses	Jun-2014
0003	Responses to List of Outstanding Issues	May-2014
0002	Follow-up Measures	Mar-2014
0001	Responses to List of Outstanding Issues	Feb-2014
0000	MAA	May-2014

## Annex 3: Guidance and Best Practice on the Structure of Module 3

### CTD-Quality Considerations for eCTD Submissions in Europe

#### A3-1 Introduction

This Annex is based on the use of the ICH eCTD specification v3.2. Refer to the Glossary for an explanation of terms.

The ICH eCTD Specification allows the applicant to manage eCTDs at different levels in Module 3 (please, refer to section 2.2. above). The preference should be one single eCTD application that covers all strengths of a drug product (invented name). If the applicant needs to have one eCTD application per strength or dosage form, this should be explained in the cover letter and guidance should be given there about which documentation that are duplicated in the different eCTDs to prevent duplicate of work during assessment.

#### A3-1.1 Terminology in the eCTD modul 3 XML

In addition to documents, eCTD applications provide information in the XML as follows:

- 
- Attribute: Defines new sections within the CTD table of contents (e.g. substance, manufacturer)
- Element: The CTD table of content location (e.g. m3-2-s-1-1)
- Leaf: eCTD document
- Module 3 attributes examples
  - m3-2-s-drug-substance: *substance, manufacturer*
  - m3-2-p-drug-product: *product-name, dosage form, manufacturer*
  - m3-2-p-4-control-of-excipients: *excipient*

#### A3-2 General Principles

These XML attributes describe the quality sections of the eCTD and should be chosen carefully to present the information provided to the assessor in a clear and unambiguous way. See section 3.4.1 and 3.4.2 in relation to the structure of the drug substance and drug product modules.

#### A3-2.1 Document Granularity

eCTD applications can handle different authoring strategies for CTD-Q information. For any given CTD-Q topic (e.g., P.1 Description and Composition of the Drug Product), either a single document can be provided that covers multiple strengths, or multiple documents can be provided, e.g. per strength. Regardless of the XML attributes, when there are significant differences in content it is best practice to provide multiple documents, to realise the lifecycle benefit that eCTD offers. When deciding on the strategy for the single- or multiple-document approach applicants should also take into consideration the ability of the assessor to review the content. If there are multiple files in the same element, the title of each leaf should be used to distinguish the scope of each document's content, and the -var part of the filename used to differentiate each PDF document.

#### A3-2.2 Identifying to an Agency what the Application covers

Generally speaking, a single eCTD application is submitted for all strengths and forms under one tradename. In Europe, the applicant cannot cross-refer from one eCTD to another (e.g., for drug substance).

### **A3-2.2.1 Centralised Procedures**

For the Centralised Procedure, a single eCTD application should always cover all strengths and dosage forms within the procedure. A duplicate must always be submitted and maintained as a separate individual eCTD application.

### **A3-2.2.2 MR and DC Procedures**

In MRP/DCP, a single eCTD is needed per procedure that covers all involved MSs, regardless of differences in the invented name in the different countries. However, different dosage forms or strengths can be managed in separate eCTDs at the applicant's discretion, even if one combined eCTD is preferred. Applicants should carefully consider what an eCTD application will cover before submitting the first sequence.

### **A3-2.2.3 EU Envelope**

The Module 1 EU envelope provides the trade name (invented name) of the drug product. The **tracking number element**, which is repeatable, may list all of the product licences or application numbers covered by the eCTD. Applicants should ensure that the values for invented name, INN Applicant and Application Number in the EU envelope are complete and consistent. **Note:** The Application Number and INN may not be known at the time of the first submission and may have to be substituted in later sequences.

## **A3-3 Module 3 XML Attributes in the eCTD**

### **A3-3.1 Choosing Module 3 XML Attributes**

The XML attributes reflect the document granularity used in Module 3. The actual words for the attributes need not be an exact match of the words used in the content of Module 3 documents, but should clearly describe the content in that specific section of the dossier. More than one entry for any attribute generally results in the replication of the relevant portion of both the XML and the folder architecture, (e.g., 3.2.S Drug Substance, 3.2.P Drug Product, 3.2.P.4 Control of Excipients, 3.2.A.1 Facilities and Equipment, 3.2.A.2 Adventitious Agents Safety Evaluation, 3.2.A.3 Excipients).

Module 3 XML attributes cannot be changed with later submissions within the same application without losing the lifecycle benefit that eCTD offers. For example, if an applicant builds an eCTD with "ABC Chemical" as the manufacturer of the drug substance, and subsequently changes drug substance manufacturer to "XYZ Chemical", they would normally provide a new eCTD sequence with "XYZ Chemical" as an additional module 3 XML attribute. It will not be possible to have content in the "XYZ Chemical" section that replaces or appends to content in the "ABC Chemical" section. This is because in the eCTD it is not possible to apply lifecycle across different sections. However, it will be possible to delete some or all of the content within the "ABC Chemical" section, if required.

### **A3-3.2 Drug Substance (32s) Attributes**

The use of these attributes is mandatory. Refer to [ICH eCTD Q&As #65-70](#) for guidance. (Change control section at bottom of page).

#### **A3-3.2.1 Example – One Drug Substance, two Drug Substance Manufacturers, two Finished Product Manufacturers, one Dosage Form**

In this example, there are two drug substance manufacturers, which each hold an ASMF on the drug substance. The MAH/Applicant should create three drug substance modules in their eCTD dossier:

- The Applicant's part of ASMF 1 in one drug substance module (m32S section).
- The Applicant's part of ASMF 2 in one drug substance module (m32S section).
- The Applicant's control of the active substance in *one* drug substance module (m32S section), which covers both sources of the drug substance.

The drug product module should be compiled covering both finished product manufacturers i.e. there should only be one drug product module:

- Drug product (m32P section)

Drug substance:	INN
Finished product:	INVENTED NAME 400 mg film-coated tablets
Drug substance manufacturers:	Y (ASMF holder 1) X (ASMF holder 2)
Finished product manufacturer:	Z and A

- m3-quality
  - m3-2-body-of-data
    - m3-2-s-drug-substance [manufacturer: X] [substance: INN]
    - m3-2-s-drug-substance [manufacturer: Y] [substance: INN]
    - m3-2-s-drug-substance [manufacturer: Applicant] [substance: INN]
    - m3-2-p-drug-product [manufacturer: All] [product name: INN] [dosage form: 400-mg-FCT]

The manufacturer of the drug product is stated as “all” as the documentation is compiled and covers all drug product manufacturers of this specific dosage form. ‘

### **A3-3.3 Drug Product (32p) – Product/Dosage Form/Manufacturer**

The use of these attributes is optional. Refer to [ICH eCTD Q&As #68, 69 and 70](#) for guidance.

#### **A3-3.3.1 Drug Product Name**

Since the M1 EU envelope contains the invented name, it is not necessary to use this name in the product name XML attribute that is used in Module 3. Applicants should take into consideration that trade names can occasionally change over time. If the trade name is not well established, applicants should consider alternatives such as ‘active’, or ‘product’. Alternatively, the internal company code of the drug product name may be used. If applicable, additional attributes can be used as needed (e.g. ‘diluent’ or ‘placebo’).

This attribute then results in a full set of 3.2.P.1 to 3.2.P.8 XML elements and folders.

#### **A3-3.3.2 Dosage Form**

In conjunction with the above product name, each additional dosage form entry results in an additional full set of 3.2.P.1 to 3.2.P.8 XML elements and folders. When deciding on the degree of detail (e.g., ‘tablet’ vs. ‘film-coated tablet’, ‘frozen’ vs. “refrigerated” formulation for vaccines), consider the potential for future line extensions and the proportion of drug product documents that could be re-used. If that proportion is small, then consider an initial specific dosage form entry, e.g. ‘film-coated tablet’ rather than ‘tablet’.

Strength(s) need not be mentioned in the attribute. Not all 3.2.P documents are, nor need to be, strength dependent. For example, for a common granulation for six strengths, many documents would have nearly identical content; little benefit would be derived from having strength-specific documentation. However, if there is a chance that some strength(s) may not be approved or may be later handled in another eCTD application, then some CTD topics might benefit in having separate leaves per strength (e.g.3.2.P.5.1 Specification).

#### **A3-3.3.3 Drug Product Manufacturer**

Normally, there should only be one drug product manufacturer section in an eCTD dossier. A general term for the attribute such as ‘all’ or ‘applicant’ is acceptable.

However, for some product types, e.g. biotechnological products, there might be relevant to have multiple drug product manufacturer sections. If used and in conjunction with the above product name and dosage form, each manufacturer entry results in a set of 3.2.P.1 to 3.2.P.8, 3.2.A.1 or 3.2.A.2 XML elements with appropriate directory folders.

### **A3-3.4 Excipients**

The use of these attributes is optional. Detailed guidance is provided in the ICH eCTD IWG Question and Answer and Specification Change Request Document, Q&A #72-75 (link in previous section)

#### **A3-3.4.1 Excipients of Human or Animal Origin and Novel Excipients**

Content under sections 3.2.P.4.5 & 3.2.P.4.6 should be provided under an additional attribute such as 'animal-human-novel', refer to ICH eCTD Q&A #73. Note, the files provided under this section should not be in a subfolder to the 32p4-contr-excip folder in the directory structure. Refer to the 'File and Folder Structure Names' worksheet in the eCTD validation rules.

## **Annex 4 Management of Parallel Variations in the eCTD**

### **A4-1 Background**

Parallel variations are variations on-going within a single product lifecycle at the same point in time that are modifying the same content. Tracking these variations and modification of the content representing the current-approved baseline represents a particular business challenge within eCTD.

This annex presents the recommended approach for managing parallel variations in accordance with the ICH and EU eCTD Specifications.

### **A4-2 Business Challenge**

Parallel variations occur when more than one variation is submitted modifying the same approved content, the first of which has not been approved before the next is submitted. Upon approval of one of the variations, the approved content has changed. The remaining pending variations contain proposed content that may be based upon the originally approved content or on the newly approved content. The applicant must track each separate approval and update the content for each pending variation.

The specific challenges associated with this sequence of events are as follows:


- (i) Tracking the approved content
- (ii) Tracking separate on-going variations
- (iii) Tracking individual or combined approvals for each variation

### **A4-3 Best Practice**

Two options are described in this Q&A. Option 1 is the classic approach to eCTD lifecycle management, where a single document is replaced by a different, updated version, at the initial submission. Option 2 involves leaving the 'approved' content in the eCTD, but introducing 'proposed' documents into the lifecycle, until the outcome of the assessment is clear, and only then replacing the original 'approved' content. This Q&A can provide no guidance on when to use the technique described in option 2, and when to assume that a variation is not happening in parallel, and therefore to use option 1, submitting the proposed content as a leaf with the 'replace' operation attribute. Applicants need to consider whether or not it would be appropriate to use the one or the other option outlined in this guidance on a case-by-case basis.



## A4-4 Description of Figures



**Figure 2 (A4): Description of elements**

### A4-4.1 Use of one Lifecycle (Option 1)

This option describes the classic eCTD lifecycle management approach, where existing content is replaced with revised content. When there is only one change and variations do not occur in parallel, and the change is approved, the advantage of this approach is that applicants do not have to follow up with another 'consolidation' sequence after approval, because they have already replaced the content and the current view of the eCTD will be correct.

**Figure 3 (A4) : Use of one document lifecycle**

	<b>MAA &amp; Variations</b>
0000 (MAA) (related sequence – none)	Document 1 ( <del>New</del> )
0001 (Variation 1) (related sequence – none)	Document 1 Proposal 1 ( <del>replace</del> )
0002 (Variation 2) (related sequence – none)	Document 1 Proposal 2 ( <del>replace</del> )
<b>eCTD Viewer Current View</b>	
0000	Document 1 (New) (0000)
0000 - 0001	Document 1 Proposal 1 ( <b>replace</b> ) (0001)
0000 - 0002	Document 1 Proposal 2 ( <b>replace</b> ) (0002)

#### A4-4.1.1 Drawbacks of Option 1

##### Approval Status and Clarity on the Basis for Further Changes

If option 1 is used, and the most recently submitted document is replaced, regardless of its regulatory status, then it becomes unclear what has been approved, and therefore what the

changes in the incoming new submission are based upon. In this example, it is unclear whether Proposal 2 is based on the content from Proposal 1 or the content from the original Document 1 in sequence 0000. Therefore, when using this approach, if a second variation is submitted before the first is finalised, applicants should specify which document the changes in the second variation are based on.

### **Impact of Regulatory Outcome**

If the operation attribute 'replace' is used in each variation as described in Figure 1, then depending on the progress of the review/approval/rejection of each variation, the eCTD lifecycle may not correctly represent the current or most appropriate lifecycle. For example, if variation 2 were to be approved first, the documentation of variation 1 where changes were based on the content in sequence 0001 may no longer be displayed appropriately. If variation 1 is rejected, and variation 2 was based on changes versus the content in variation 1, the content of variation 2 might be difficult to evaluate.

If either variation 1 or 2 (or both) is rejected, a new sequence has to be submitted reflecting only the approved content.

One advantage of this approach is that if both variations are approved, no additional sequence has to be submitted.

## **A4-4.2 Creation of separate Approved and Proposed Document Lifecycles (Option 2)**

This option can be used in any situation where parallel variations are expected, but this is specifically recommended when submitting labelling changes in the Centralised Procedure, and the terminology used here is therefore specific to the SmPC in Centralised applications. When an applicant expects parallel variations to be submitted, the proposed document for the variation is not submitted as a replacement of the original (approved) content. Instead of using operation attribute "replace", a new document lifecycle is created for each proposed document by submitting it with a title identifying its proposed status and a very brief description of the change being proposed, and an operation attribute of "new". Proposed content submitted in this way can only be submitted as a "new" document or replace other proposed content in the same location. The approved content in this CTD section has a separate lifecycle, and has a title indicating it is the approved document. This means that eCTD viewing tools will allow viewing of both the approved and proposed content alongside each other in the eCTD "current" view. Specifically, for the m1.3.1 section of the dossier in the Centralised Procedure 'approved' documents are labelled with either 'Final Opinion' or 'Commission Decision' in the leaf title, depending on the stage of the review that resulted in the final agreed labelling. Variations are then submitted as 'new' documents, not replacing this approved content, with appropriately descriptive leaf titles, for example, "Type II Variation Section 4.4 Update June 2020 - Proposed".

### **A4-4.2.1 Addition of further proposed Document Lifecycles (parallel variations)**

If, during the review of the first variation, there is a subsequent variation that also proposes changes to the same content, this is also submitted with an operation attribute of "new", and a title indicating that the document being provided is another proposal. The document submitted in the second proposal should reflect changes made versus the current approved document (in this example, the current decision); the document does not contain the changes from Variation 1. The leaf title should differentiate it from the former proposed document from the previous variation. Assigning descriptive title attributes will allow the proposed document in each variation to be identified by viewing tools displaying the "current" view.

Figure 3 illustrates how the "current" view is able to display each of two parallel variations, when the title attribute is specific to the variation and the operation attribute "new" is used as described.

**Figure 4 (A4) : Use of separate document lifecycles with different title attributes**

	<b>Original MAA</b>	<b>Final Opinion or Decision Only</b>	<b>Variation 1</b>	<b>Variation 2</b>
0000 (rel sequence – none)	Proposed SmPC ( <b>New</b> )			
0001 (rel sequence – 0000)	RTQ 120 changes to SmPC ( <b>Replace</b> )			
0002 (rel sequence – 0000)	RTQ 180 changes to SmPC ( <b>Replace</b> )			
0003 (rel sequence – 0000)		SmPC (English) Decision Jan 2020 ( <b>Replace</b> )		
0004 (rel sequence – none)			Type II Variation Section 4.4 Update June 2020 - Proposed ( <b>New</b> )	
0005 (rel sequence – none)				Type II Variation Section 4.6 Update July 2020 - Proposed ( <b>New</b> )
<b>eCTD Viewer Current View</b>				
0000	Proposed SmPC ( <b>New</b> ) (0000)			
0000 - 0001	RTQ 120 changes to SmPC ( <b>Replace</b> ) (0001)			
0000 - 0002	RTQ 180 changes to SmPC ( <b>Replace</b> ) (0002)			
0000 - 0003	SmPC (English) Decision Jan 2020 ( <b>Replace</b> ) (0003)			
0000 - 0004	SmPC (English) Decision Jan 2020 ( <b>Replace</b> ) (0003) Type II Variation Section 4.4 Update June 2020 – Proposed ( <b>New</b> ) (0004)			
0000-0005	SmPC (English) Decision Jan 2020 ( <b>Replace</b> ) (0003) Type II Variation Section 4.4 Update June 2020 – Proposed ( <b>New</b> ) (0004) Type II Variation Section 4.6 Update July 2020 - Proposed ( <b>New</b> ) (0005)			

**A4-4.2.2 Upon Approval of a Single Variation – Deletion and Replacement**

Upon approval of any variation, the proposed content is deleted, and the original (approved) content is replaced with a document containing the revised content. Current view will then show the newly approved content, but also any outstanding proposals, as shown in Figure 4 and Figure 5. This additional sequence should be considered part of the same regulatory activity as the proposal that has been approved.

**Figure 5 (A4) : Replacement of approved content by newly approved content, and deletion of proposed content**

In this example, commission decision received in December 2020 incorporates the changes from the Type II variation submitted in sequence 0004 only. The changes from the Type II variation in sequence 0005 are still under review. In sequence 0006, the 'proposed' label from the first variation is deleted and the new commission decision is provided, replacing the original commission decision from sequence 0003. The content of the second variation is also amended in sequence 0006, to reflect the newly approved content in section 4.4, alongside the still unapproved change in section 4.6, and left in the lifecycle as an outstanding proposal.

	MAA	Final Opinion or Decision Only	Variation 1	Variation 2
0003 (rel sequence – 0000)		SmPC (English) Decision Jan 2020 <b>(Replace)</b>		
0004 (rel sequence – none)			Type II Variation Section 4.4 Update June 2020 - Proposed <b>(New)</b>	
0005 (related sequence – none)				Type II Variation Section 4.6 Update July 2020 - Proposed <b>(New)</b>
0006 (rel sequence – 0004, 0005)		SmPC (English) Decision Dec 2020 <b>(Replace)</b>	Type II Variation Section 4.4 Update June 2020 - Proposed <b>(Delete)</b>	Type II Variation Section 4.6 + inclusion of approved Type II Variation Section 4.4 Update Dec 2020 – Proposed <b>(Replace)</b>
<b>eCTD Viewer Current View</b>				
0000 - 0005	SmPC (English) Decision Jan 2020 <b>(Replace)</b> (0003) Type II Variation Section 4.4 Update June 2020 - Proposed <b>(New)</b> (0004) Type II Variation Section 4.6 Update July 2020 - Proposed <b>(New)</b> (0005)			
0000 - 0006	SmPC (English) Decision Dec 2020 <b>(Replace)</b> (0006) Type II Variation Section 4.6 Update Dec 2020 - Proposed <b>(Replace)</b> (0006)			

**Figure 6 (A4): Progression on the 2nd Parallel Proposal**

In this example, as the procedure progresses, the proposed change to section 4.6 needs to be further amended as a result of the regulatory review (e.g. updated wording as suggested by the assessor), and this amendment is done with a replacement document in sequence 0007. Once a decision is reached, another sequence, 0008, is submitted, including the new decision replacing the one submitted in sequence 0006, and a deletion of the section 4.6 proposal, as amended by sequence 0007.

	MAA	Final Opinion or Decision Only	Variation 1	Variation 2
0003 (rel sequence – 0000)		SmPC (English) Decision Jan 2020 <b>(Replace)</b>		
0004 (rel sequence – none)			Type II Variation Section 4.4 Update June 2020 - Proposed <b>(New)</b>	
0005 (rel sequence – none)				Type II Variation Section 4.6 Update July 2020 - Proposed <b>(New)</b>
0006 (rel sequence – 0004, 0005)		SmPC (English) Decision Dec 2020 <b>(Replace)</b>	Type II Variation Section 4.4 Update June 2020 - Proposed <b>(Delete)</b>	Type II Variation Section 4.6 + inclusion of approved Type II Variation Section 4.4 Update Dec 2020 – Proposed <b>(Replace)</b>
0007 (rel sequence – 0005)				Type II Variation Section 4.6 + inclusion of approved Type II Variation Section 4.4 Update January 2021 – Proposed <b>(Replace)</b>
0008 (rel sequence – 0005)		SmPC (English) Decision Mar 2021 <b>(Replace)</b>		Type II Variation Section 4.6 + inclusion of approved Type II Variation Section 4.4 Update January 2021 – Proposed <b>(Delete)</b>
<b>eCTD Viewer Current View</b>				
0000 - 0006	SmPC (English) Decision Dec 2020 <b>(Replace)</b> (0006) Type II Variation Section 4.6 Update Dec 2020 - Proposed <b>(Replace)</b> (0006)			
0000 - 0007	SmPC (English) Decision Dec 2020 <b>(Replace)</b> (0006) Type II Variation Section 4.6 Update Jan 2021 - Proposed <b>(Replace)</b> (0007)			
0000-0008	SmPC (English) Decision Mar 2021 <b>(Replace)</b> (0008)			

**A4-4.2.3 Approval of Multiple Variations at the Same Time**

There will be occasions where multiple changes are approved at the same time, or within a very short time period. In these instances, it would not be appropriate to submit separate ‘approved’

content for each variation; instead, a consolidated document representing all the approved changes should be submitted. This would replace the existing 'approved' content. The eCTD sequence containing the new approved content would also contain leaves deleting the relevant 'proposed' documents, as illustrated in Figure 5.

**Figure 7 (A4): Replacement of approved content by newly approved content, and deletion of multiple proposed documents**

In this example, commission decision received in December 2020 incorporates the changes from the Type II variation submitted in sequence 0004, and also the changes from the Type II variation in sequence 0005. In sequence 0006, both 'proposed' documents from the variations are deleted and the new commission decision is provided, replacing the original commission decision from sequence 0003. This leaves only the latest commission decision from sequence 0006 in the current view. While creating a combined closing sequence covering multiple commission decisions is allowed, adding other regulatory activities into this closing sequence, e.g. to include a consolidation, is not acceptable.

	MAA	Final Opinion or Decision Only	Variation 1	Variation 2
0003 (related sequence – 0000)		SmPC (English) Decision Jan 2020 ( <del>Replace</del> )		
0004 (related sequence – none)			Type II Variation Section 4.4 Update June 2020 - Proposed ( <del>New</del> )	
0005 (related sequence – none)				Type II Variation Section 4.6 Update July 2020 - Proposed ( <del>New</del> )
0006 (related sequence – 0004 & 0005)		SmPC (English) Decision Dec 2020 ( <b>Replace</b> )	Type II Variation Section 4.4 Update June 2020 - Proposed ( <b>Delete</b> )	Type II Variation Section 4.6 Update July 2020 - Proposed ( <b>Delete</b> )
<b>eCTD Viewer Current View</b>				
0000 - 0005	SmPC (English) Decision Jan 2020 (Replace) (0003) Type II Variation Section 4.4 Update June 2020 - Proposed ( <b>New</b> ) Type II Variation Section 4.6 Update July 2020 - Proposed ( <b>New</b> )			
0000 - 0006	SmPC (English) Decision Dec 2020 ( <b>Replace</b> )			

**A4-4.2.4 Rejections or Withdrawals**

If any proposed changes are rejected or withdrawn by the applicant, then the applicant can provide a sequence deleting the "proposed" content document, but not providing any replacement for the original approved document.

**A4-4.2.5 Typical Applications**

An applicant is most likely to need to submit parallel variations on dossier content that changes more often, such as the SmPC or the Risk Management Plan (RMP<sup>1</sup>). However, this guidance is not limited to use in these parts of the dossier. Applicants should also note that many variations affecting the SmPC and RMP will not occur in parallel with another variation, and at times, when a variation is initially expected to be completed in isolation, a second parallel variation may become necessary at a later stage.

## Document Control

### Change Record

Version	Author(s)	Comments
1.0	TIGes eCTD guidance topic group	This document has been prepared by the eCTD Guidance Topic Group of the TIGes. It is largely based on the NeeS guidance document 1.4.
1.1	TIGes Harmonisation Group/ GW, AN, KG, KM	First draft for revision, made the document in line with agreed text in the NeeS guidance and with the New validation criteria, TIGes Harmonisation group 110309
1.2-1.93	AN, KG, MC, KM, BT, KP	Further revisions by TIGes Harmonisation group TC meetings in April-July 2011
1.94	KG	Further revision after TIGes comments and minor update in accordance with EU M1 eCTD specification draft v.1.4.1.
2.0	KG, AN	Following review of TIGes comments and final updates at subgroup TC meeting in August. Final document for TIGes adoption and publication.
2.1-	TIGes Harmonisation Group// KG, AN	Draft for Second revision, made the document in line with agreed text on Q&A, EU M1 Spec v2.0, and in the NeeS guidance and with the updated validation criteria, TIGes Harmonisation group 12/2012-07/2013
2.7	AN, KM	Following review comments edits have been included.
3.0		
3.1	AN, KM, KG, KP	Preparing the revision to accommodate regulatory changes, improvements and clarifications, editions due to inconsistencies caused by revisions of the EU M1 spec. v3.0, eCTD validation criteria 6.0, eAF usage and further modifications
3.2	KM	Consolidating all changes and formatting modifications
3.3	HHMG	Reviewing modified sections and tidying up comments
3.4	KM	Preparation for publication
4.1-4.14	HHG members//KG	Preparing for update to a more current version and to reflect new EU M1 eCTD specification and Q&As that have been published since the latest update 2016.
4.15	KG and HHG members	Final draft after CMDh comments. Sent for final review by the eSubmission Expert Group before adoption.
5.0	KG	Cleaned final version for adoption. No content changes from 4.15.

### Reviewers

Version	Name	Organisation / action
1.0	TIGes	TIGes eCTD Topic Group
1.1-1.92	Members of the subgroup	TIGes Harmonisation group
1.93	Members of TIGes	TIGes
1.94	Members of the subgroup	TIGes Harmonisation group
2.0	Members of subgroup And the TIGes	TIGes for adoption
2.6	Members of the TIGes	TIGes for adoption as v.3.0
3.1	Members of HHMG	Human Harmonisation Maintenance Group
3.2	EMA	EMA
3.3	The members of the HHMG and the eSubmission CMB	Human Harmonisation Maintenance Group eSubmission Change Management Board
4.0	The members of the eSubmission CMB	eSub CMB for adoption
4.1-4.14	Drafted and reviewed by members of the HHG	Human Harmonisation Group for drafting and seek input from their organisations
4.09	The members of the eSubmission Expert group	eSubmission Expert group for review/comments
4.14	The delegates in CMDh	CMDh for review/comments
4.15	The members of the HHG	Human Harmonisation Maintenance Group updates due to received CMDh comments. Finalising the draft.
4.15	The members of the eSubmission Expert group	eSubmission Expert group for final review before adoption.
4.15 / 5.0	All members of the eSubmission Expert group	eSubmission Expert Group for adoption (4.15 as cleaned, final version)

## Distribution

Version	Distributed to	Way of distribution
1.0	General public	Published on the EMA eSubmission website
1.1-1.92	Members of the Subgroup	E-mail April-July 2011
1.93	Members of the Subgroup and Members of TIGes	E-mail July 2011
1.94	Members of the Subgroup	E-mail August 2011
2.0	Members of the Subgroup and Members of TIGes	E-mail August 2011
3.0	Members of TIGes	E-mail August 2013
3.1	eSubmission CMB	E-mail December 2015
3.4	eSubmission CMB	E-mail March 2016
4.0	eSubmission CMB	E-mail April 2016
4.1-4.14	HHG	Continuous email conversations 2021
4.9	eSubmission Expert Group	E-mail August 2021
4.14	CMDh	E-mail October 2021
4.15	HHG	E-mail November 2021 (final including comments)
4.15	eSubmission Expert Group	E-mail December 2021
5.0	eSubmission Expert Group	E-mail December 2021 (final version for adoption)

## Coming into Operation

Version	Date in operation	Comment
1.0	May 2009	This document is specifically called a “Draft for Testing”. The Topic Group fully anticipate comments from NCAs and applicants which will enable future versions to reflect practical experience of users. In this way the document will evolve to become an essential work of reference in this area.
2.0	1 September 2011	Published at the EMA eSubmission website for use
3.0	2 September 2013	Published at the EMA eSubmission website for use
4.0	1 July 2016	Published at the EMA eSubmission website for use
5.0	1 February 2022	Published at the EMA eSubmission website end of December

---